Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
10-6-2020 1:00 PM

Quinone Reductase 2 Roles in Proteomic Regulation and
Response to Treatment with Clinical Drugs
Matthew D. Walker, The University of Western Ontario
Supervisor: Shilton, Brian H., The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Biochemistry
© Matthew D. Walker 2020

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Biochemistry Commons

Recommended Citation
Walker, Matthew D., "Quinone Reductase 2 Roles in Proteomic Regulation and Response to Treatment
with Clinical Drugs" (2020). Electronic Thesis and Dissertation Repository. 7379.
https://ir.lib.uwo.ca/etd/7379

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Detoxification of quinone compounds is catalyzed by the NQO1 protein in humans.
The related NQO2 is distinct from NQO1 as it uses NRH preferentially as a co-substrate to
the exclusion of NAD(P)H. It is uncertain if NRH is available in cells for use by NQO2 and
raises doubts that quinone detoxification is the adaptive role for NQO2. This study employed
cell biology, protein structure and proteomics approaches to identify functions for NQO2
relevant to a cellular context. Several NQO2 interacting clinical drugs were found to have
cytotoxic effects dependent upon NQO2 expression. Results from proteomic experiments
identified novel roles for NQO2 in regulating lysosome and exosome proteins. Taken
together the findings of this thesis are consistent with the hypothesis that NQO2 plays an
alternative role in cells. NQO2 is proposed to function as a regulator of various cellular
functions by acting as a redox switch rather than a quinone reductase.
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Sunitinib, Protein structure, Cellular toxicity, Apoptosis, Combination index, X-ray
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Summary for Lay Audience
Quinone reductases are a class of proteins that perform detoxification roles in the cell.
Specifically, they catalyze a two-electron reduction of quinone containing compounds.
Quinones are prone to forming harmful byproducts that contribute to oxidative stress in cells
thus, quinone reductase enzymes are required to detoxify such compounds. Humans have two
quinone reductase enzymes; NQO1 and NQO2. NQO1 is well documented as functioning as
a detoxification enzyme while the evidence regarding NQO2 function suggests that it is not
able to perform its catalytic function with the co-substrates available in cells. The structural
features of NQO2 make it unable to use NAD(P)H efficiently and it can only perform
reductions of quinone compounds when provided with exogenous co-substrates. NQO2 is
further notable for being a prominent target of a wide range of drugs used clinically. Many
kinase inhibitors have been documented to bind to NQO2 but it is unclear why so many
drugs would have such great affinity for the protein and what the cellular implications of the
interactions are. The clinical drugs that bind to NQO2 are often used to treat various types of
cancers or infections therefore, understanding how NQO2 contributes to the mechanisms of
such drugs is important to optimizing their use clinically. This project focuses on
investigating how NQO2 influences the cellular toxicity of a variety of drugs that have been
documented to bind to the protein. It also reports novel structures of sunitinib, a recently
identified NQO2 interacting drug, bound to the NQO2 protein that will further the
understanding of NQO2 interactions with clinical drugs. Differences in the proteomes of
cells that express NQO2 versus cells that have the gene for the protein knocked out were also
identified and points towards novel roles for the protein in regulating the function of
lysosomes and exosomes. This thesis is impactful as it will contribute towards identifying
cellular functions for NQO2 and will inform the study and use of clinical drugs that interact
with the protein.
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Chapter 1 – Introduction and Background

1

Introduction
The N-Ribosyldihydronicotinamide:Quinone Reductase 2 (NQO2) protein is

designated as a quinone reductase enzyme; however, the mystery surrounding this protein
questions the detoxification function proposed for it. NQO2 is peculiar as it is the only
flavin-dependent quinone reductase known to preferentially utilize small nicotinamide
derivatives. First identified in 1962, NQO2 was notable for being a mammalian flavoprotein that reduced quinones using dihydronicotinamide riboside (NRH) rather than the
widely used co-factors NAD(P)H (1). The “NQO2” label was not given to this protein
until decades later when it was identified as having a 49% sequence similarity to
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) and was thus included within the same
family as this traditional quinone reductase (2). Though classified as a quinone reductase
it is not known if NQO2 functions as an enzyme within cells because, it is uncertain
whether NRH is available at appreciable levels within cells to act as an electron donor for
NQO2 (3). A role for NQO2 under physiological conditions has yet to be identified
though there are multiple pieces of evidence to suggest NQO2 is adapted for flavin-redox
switch signaling. The similarities of NQO2 to the yeast quinone reductase (Lot6p), the
high affinity binding of kinase inhibitors to NQO2, and the induction of conformational
changes to the protein by small molecule binding are observations that point towards
signaling roles for the protein in addition to quinone detoxification (4,5,6). This study
aims to identify possible functions for NQO2 that are relevant within a cellular context
and make sense of the distinct characteristics observed in NQO2.

2

1.1 The Function of Quinone Reductases
Proteins within the quinone reductase family catalyze the two-electron reduction
of quinone compounds. Generally, though with some exceptions, the reaction proceeds
via a ping-pong reaction mechanism wherein an electron donor (co-substrate) will first
reduce the flavin molecule bound to the protein. The electron donor then leaves the active
site, making it available for a quinone substrate. Substrates in the active site will then be
reduced by the flavin molecule, which donates two electrons to the quinone (7). The
reaction produces a dihydroquinone compound and follows a full cycle of the protein
from an oxidized state, to a reduced state, then returning to an oxidized state (Figure 1).

Figure 1: General Ping-Pong Reaction Mechanism of Quinone Reductase Enzymes.
The two-electron reduction of quinones to dihydroquinones is catalyzed by quinone reductase enzymes.
The reaction proceeds in a ping-pong reaction mechanism. Flavin molecules bound to the enzymes are first
reduced by electron donors. After the electrons have passed to the flavin the donor leaves the active site and
a quinone compound can enter. The reduced flavonoid then donates electrons to the quinone thus reducing
it to a dihydroquinone.

Through the two-electron reduction of quinones to dihydroquinones, quinone
reductases function to detoxify the compounds (8). Such a function is necessary to protect
cells from the formation of reactive oxygen species (ROS) that can occur from an
abundance of semiquinones. Semiquinones are free radical intermediates that occur from
single-electron reduction of quinone compounds, quinone reductases guard against the
buildup of such molecules (9).

3

1.1.1

Prevalence of Quinone Reductases

The NQO1 and NQO2 genes are found in mammals and are responsible for encoding
their respective quinone reductase. It is interesting to note that the NQO2 gene appears to
have arisen sometime near the point when amniotes emerged evolutionarily. Species of
frogs and zebrafish have been shown to possess NQO1 however, NQO2 genes have yet to
be identified – birds and reptiles appear to have both genes though some species have
been shown to only have NQO2 (10). Quinone reductase enzymes have also been
characterized in all forms of life, (such as plants, fungi and bacteria) having both
similarities and unique differences to the proteins found in mammals.
Yeast (Saccharomyces cerevisiae) express Lot6p which in addition to quinone
reductase function has been shown to have roles is signaling, particularly apoptotic-like
cell death (4,11). Like the quinone reductases in humans, Lot6p functions as a dimer
however, it is associated with flavin mononucleotide (FMN) as a cofactor rather than
flavin adenine dinucleotide (FAD) (12). Plants also have arrays of quinone reductase
enzymes and it is believed such enzymes were crucial in the early evolution of
photosynthesis (13). Arabidopsis thaliana for instance is known to have
NAD(P)H:quinone reductase (NQR) and Flavodoxin-like quinone reductase 1 (FQR1)
(13,14). Both of these enzymes utilize FMN as a cofactor and have been demonstrated to
catalyze the two-electron reduction of quinones in vivo. Highlighting the ancient origins
of the quinone reductase family of enzymes, there are numerous quinone reductases that
have been characterized in bacteria. It has been demonstrated in Escherichia coli that
culturing with menadione or other quinone compounds increases the quinone reductase
activity and the abundance of quinone reductases in the bacteria (15,16). This observation
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is intriguing because menadione is a well characterized substrate of both NQO1 and
NQO2 and may contribute to signaling events involving both proteins (7). The
tryptophan (W) repressor-binding protein (WrbA) and acyl carrier protein
phosphodiesterase (AcpD) are two of the quinone reductases characterized in E. coli and
confirmed to catalyze the two-electron reduction of quinones and each utilized FMN as
cofactors (17,18). The true extent of quinone reductases expressed by bacteria is not yet
known as many proteins once classified as azoreductases or proteins with other functions
have been shown to have quinone reductase activity (19). The identification of quinone
reductases across all forms of life is illustrative of their adaptive benefit but also
demonstrates the peculiarity of NQO2 since all, but NQO2, utilize NAD(P)H cosubstrates.

1.2

NQO2 in Relation to Other Quinone Reductases

To understand the relevant cellular functions of NQO2 it is useful to compare
what is known of this protein to other quinone reductases. The most apt protein to
compare with NQO2 is NQO1, though looking at the quinone reductases found in other
species has also revealed insights into possible roles. Investigating how NQO2 is both
similar and how it differs to other enzymes in its family may reveal a function that
corresponds to the protein’s characteristics. The most distinguishing characteristic of
NQO2 is the co-substrate preference for NRH and other small nicotinamides - a trait not
observed in any other protein (20). It is not clear why NQO2 is unable to use NAD(P)H
efficiently – having a catalytic rate of kcat/Km = 0.62 min-1 µM-1 with those co-substrates
– though there have been some insights from structural and kinetic studies (21).
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1.2.1

NQO1 and NQO2. Why have Both?
NQO1 is a well established phase 2 detoxification enzyme and is regulated in

large part by the antioxidant response element (ARE) and the xenobiotic response
element (XRE) (22,23,24). The enzyme utilizes NAD(P)H with an efficiency of kcat/Km
= 440 (min-1 µM-1) and is known to detoxify quinones such as menadione (25,26,27). A
prime example of this activity has been demonstrated by administering NQO1 knockout
mice with menadione, wherein toxicity of the compound was drastically increased
compared to mice that express NQO1 (28). Such observations definitively show that
NQO1 functions as a quinone detoxifying enzyme in vivo. In addition to quinone
detoxification NQO1 has been shown to regulate p53 degradation (29). Regulation of p53
by NQO1 occurs through direct interactions between the two proteins – an NADH
dependent event – and indirectly by NQO1 binding to the 20S proteasome, resulting in
increased p53 stability (30).
As previously mentioned NQO1 and NQO2 are functional dimers and share about
a 49% sequence identity at the protein level which led to the assumption they would
function similarly (2). Despite their sequence similarity there are notable differences
between the structure and function of these related proteins. For instance, NQO1
possesses an extended C-terminal tail that is not common in quinone reductases and
accounts for the molecular weight difference between NQO1 and NQO2, ≈31 kDa and 26
kDa respectively (1,31) (Figure 2 (a.)). The C-terminal was not thought to be relevant to
the enzymatic activity of the protein – as many quinone reductases function normally
without it – however removal of the domain results in drastically reduced catalytic
efficiency and makes NQO1 less resistant to protease treatment (25,32). It is not entirely
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clear how the presence or absence of this C-terminal domain governs protein function
but, some insight has been gained through engineering chimeras of both these proteins –
a subject discussed later in the section (Section 1.2.3).
An additional structural difference can be seen near the active site of the enzymes.
In NQO2 the FAD binding pocket is tighter, with a bridge going over the molecule
caused by a hydrogen bond between an asparagine and glutamic acid residue. A
comparable feature is not observed in NQO1 structures (33) (Figure 2 (b-c.)). For this
reason, NQO1 may be more permissive of FAD binding or be more accommodating of
different conformations (34). It remains unclear how the differences between these
enzymes leads to their respective co-substrate preference.
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Figure 2: Structural Comparison of NQO1 and NQO2
The structural similarities and differences of NQO2 (PDB:1QR2) and NQO1 (PDB:1D4A) observed in
PyMOL. a.) Structural alignment of NQO2 and NQO1. NQO2 is displayed in yellow and NQO1 is shown
in cyan with the C-terminal tail region depicted in dark blue. b.) An active site of the NQO2 dimer is
depicted. Subunit 1 is shown in orange, subunit 2 is shown in green, the FAD co-factor is visualized in
yellow. NQO2 is shown as a surface representation and FAD as stick representation. c.) An active site of
the NQO1 dimer is depicted. Subunit 1 is shown in blue, subunit 2 is shown in red, the FAD co-factor is
visualized in yellow. NQO1 is shown as a surface representation and FAD as stick representation.

Where NQO1 has been shown to protect against the toxicity of compounds with a
quinone moiety, such as menadione, the presence of NQO2 has been shown to lead to
greater sensitivity towards such compounds (28). Mice with NQO2 knocked out have
also been subjected to menadione treatment. The results indicate that the wildtype mice
actually fare worse, in terms of treatment survival, than the knockout mice (35). This
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suggests that NQO2 can enhance the toxicity of menadione either through a signaling
event or direct activation of the compound. It is not uncommon for quinone reductases to
activate some compounds rather than detoxifying them however, the inverse relationship
between NQO1 and NQO2 with menadione is of note.
NQO1 is known to activate mitomycin C, where the 2-electron reduction by
NQO1 results in a toxic alkylating agent (36). The ability of quinone reductases to
perform bioactivation reactions has been exploited to develop chemotherapy drugs that
target types of cancers where NQO1 or NQO2 may be upregulated (37). The drug 5(aziridin-l-yl)-2,4-dinitrobenzamide (CB1954) was a promising bioactivation agent due
to its high toxicity towards Walker tumor cells in rats. Efforts to translate the drug for use
in humans were stalled by the fact that NQO1 in humans inefficiently reduced CB1954
(38). The recognition of NQO2 as a second quinone reductase in humans salvaged the
drug as NQO2 was shown to be very effective at catalyzing the bioactivation of CB1954
but only when NRH (or another electron donor compatible with NQO2) was coadministered (39). Without the addition of NRH even cells transfected with NQO2 and
treated with CB1954 did not have increased sensitivity to the drug, thus further
demonstrating that NQO2’s preferred co-substrates are not endogenous to cells (21).
Where NQO1 is a well characterized detoxifying enzyme, NQO2 has a yet unknown
function under normal cellular conditions. NQO2 is capable of detoxifying quinones but
in many instances it acts – in contradiction to its proposed function – as a bioactivator of
harmful compounds (40). Whether it toxifies or detoxifies quinones is supposedly
irrelevant in most biological contexts as its activity requires the addition of exogenous
co-substrates, whereas NQO1 utilizes NAD(P)H which is readily available in cells.
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1.2.2

Learning from Lot6p in Yeast
The quinone reductase found in yeast, Lot6p, closely resembles those found in

humans. Structurally Lot6p is more akin to NQO2 as they both fall into the class of
quinone reductases that do not have an extended c-terminal tail, unlike NQO1 (7). Lot6p
does catalyze the 2-electron reduction of quinones to dihydroquinones however, kinetics
data indicates that it is an inefficient enzyme. Using NAD(P)H as a co-substrate Sollner
et al. determined that the first half of the ping-pong reaction – the oxidation of cosubstrate and reduction of flavin on the enzyme – occurred at a rate only slightly above
an uncatalyzed reaction and the second step of the reaction – oxidation of flavin on the
enzyme and reduction of quinone – proceeds with rates below what is expected for a nonenzymatic reduction of quinones (4). There is evidence that NQO2 is capable of using
NAD(P)H under some circumstances, such as the nitroreduction of CB10-200, but
generally the traditional co-substrates are very inefficiently utilized – to a greater degree
than even Lot6p (41). In this regard Lot6p and NQO2 are rather similar in that they are
adapted to be rather poor enzymes in most cellular conditions.
The observation that Lot6p functions inefficiently as an enzyme led Sollner et al.
to theorize that Lot6p has evolved to function preferentially as a flavin-redox switch
(12,42). By interacting with the 20S proteasome, Lot6p has been shown to prevent Yap4p
– a yeast transcription factor – degradation and promote the oxidative stress response
pathway (4). This response is dependent upon the redox status of Lot6p indicating that
the conformation of the protein influences its ability to act as a signaling molecule (42).
Lot6p has further been shown to modulate apoptosis-like cell death in yeast
demonstrating an ability for the protein to influence signaling pathways (43). There is
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some evidence to suggest that NQO2 is also able to interact with the 20S proteasome and
protects p53 from degradation similarly to NQO1 (44). Further evidence is needed as
some of the results showing this effect require the addition of NRH though it remains
possible that NQO2 could be capable of detecting the redox status of the cell through
NAD(P)+/NAD(P)H ratios (45). Nevertheless, it is possible that NQO2 has evolved to
function similarly to Lot6p and flavin-redox switch function remains a plausible role for
NQO2.

1.2.3

Determinates of NQO2 Co-Substrate Preference

In order to determine what structural components are responsible for NQO2’s cosubstrate preference several studies have attempted to engineer both NQO2 and NQO1 in
an attempt to swap their respective co-substrate affinity. As stated previously, removing
the C-terminal tail of NQO1 makes the enzyme about 300 times less efficient using
NADH co-substrate. Removing the C-terminal tail also does not improve the ability to
utilize NRH (25). Chimeric NQO2 proteins have also been studied wherein the 43 amino
acid C-terminal domain of NQO1 is added to NQO2. The addition of the tail to NQO2
has no effect on NQO2’s catalytic efficiency using NRH and does little to alter the
protein’s ability to use NADH (25).
Boutin et al. have also attempted to shift the co-substrate preference of NQO2 from
NRH to NADH. They performed a number of single amino acid substitutions in four
distinct regions of the enzyme that they categorized as: active site, electron transfer, FAD
docking, and metal coordination (46). None of the mutations studied were able to alter
NQO2’s co-substrate preference however, several did have effects on the catalytic rate as
well as the ability for a melatonin analog (iodo-MCANAT) to bind to the enzyme.
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Briefly, mutation of several hydrophobic residues in the active site to tyrosines resulted in
significantly increased enzymatic activity using NRH or the synthetic nicotinamide
derivative 1-Benzyl-1,4-dihydronicotinamide (BNAH) as co-substrates. These mutations
also decreased the affinity of iodo-MCANAT while other mutations outside of the active
site increased the binding of the melatonin analog (46). Boutin et al. proposed that the
altered ability of these mutant enzymes to bind small molecules may be linked to the
redox state of the protein. The different mutations may influence the equilibrium between
redox states and could explain why some mutants have either increased or decreased
affinity for small molecules (46). Were this proposition true it would support the
hypothesis that NQO2 can function as a redox switch.
The Shilton lab has also worked on determining the structural components of NQO2
that govern its co-substrate specificity. A graduate thesis project conducted by Shahed Al
Massri aimed to shift the preference of NQO2 towards NAD(P)H using site-directed
mutagenesis (47). Two NQO2 mutants were engineered in the study, a mutant with three
amino acid substitutions (Q122G, H72V, I128Y) and a mutant protein with five amino
acid substitutions (Q122G, H72V, I128Y, E193G, N66Q). The mutations were chosen on
the basis that they differed between NQO2 and NQO1. Therefore, the mutant proteins
would resemble NQO1 more in these key sites. Both mutants had increased catalytic
efficiency with the quintuple NQO2 mutant having an approximate 70-fold increased
catalytic efficiency (using NADH as a co-substrate) compared to wildtype NQO2 (47). It
remains to be seen if these mutants have switched to have a preference for NADH over
NRH – as NQO2’s preferred co-substrate was not analyzed in the project – but it does

12

reveal key residues that contribute to NQO2’s ability to utilize conventional co-substrates
and merits further study.

1.3

Proposed Functions for NQO2

Originally discovered in 1962 as a menadione reducing enzyme that utilized NRH as
an electron donor, there is no doubt that NQO2 can function as a quinone reductase (1).
Though NQO2 does function as a quinone reductase it is not clear that this is the
biological function of the enzyme. Nearly all instances of NQO2 enzymatic activity
reported in cells requires the addition of NRH or other nicotinamide derivatives – aside
from reported activity in COS1 cells engineered to express NQO2 – thus calling into
question the protein’s role as a detoxifying enzyme (41).
There are other roles, aside from quinone reduction, that have been proposed for
NQO2 with varying levels of evidence to support them. Similarly to NQO1, it has been
proposed that NQO2 may be a regulator of p53 and thus may have roles relevant to
cancer (44). Another potential role for NQO2 is as a signaling protein. NQO2 has been
identified as the third melatonin binding site (MT3) suggesting that it may contribute to
effects produced by the hormone (48). Furthermore, NQO2 has been implicated as a
modulator of autophagy while cells are undergoing oxidative stress (49). The ability for
NQO2 to propagate redox-dependent signals would support the hypothesis that NQO2
has adaptive function as a redox-switch rather than a quinone detoxifier. Recently Dorai
et al. reported that NQO2 interacts with caveolin-1 and may influence the formation of
extracellular vesicles (50).
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1.3.1

NQO2 and Cancer
There have been two papers published that support a connection between NQO2

and the cancer regulator p53. In the paper published by Khutornenko et al. it was shown
that treatment with NQO1 or NQO2 inhibitors influenced p53 levels in response to
exposure to complex III inhibitors of the electron transport chain (ETC) (44). It was
observed that myxothiazol – a complex III inhibitor – treatment led to increasingly stable
p53 in cells. The observed p53 stability induced by this drug was abrogated when either
dicoumarol (an NQO1 inhibitor) or resveratrol (an NQO2 inhibitor) were also
administered. The result suggests that inhibiting either of the mammalian quinone
reductases leads to a destabilization of the p53 response (44). It was further shown that
treating RKO cells with myxothiazol at a 2 µM concentration induced a pronounced
nuclear localization for both NQO1 and NQO2. Though direct interactions between
NQO2 and p53 were not identified in this paper the results are highly suggestive that
modulating NQO2 activity and localization in cells has an influence on p53 stability.
Iskander et al. have also provided evidence that links NQO2 to p53 in their
experiments on Nqo2-null mice. In this study it was found that mice lacking NQO2 were
more prone to forming skin tumors as a result of treatment with 7,12-dimenthylbenz(a)anthracene (DMBA) (45). Their skin cells also had lower levels of p53, p21, and Bax
proteins as determined by western blot. Further, treatment with a carcinogen such as
benzo(a)pyrene resulted in increased p53 levels in the wild-type mice while NQO2
knockout mice have similar levels of p53 expression in their skin as when no carcinogen
is applied. The lack of p53 induction in NQO2 knockout mice and the increased
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susceptibility to skin tumor formation is suggestive of an impairment in apoptosis
induction not seen in mice that express NQO2 (45).
The evidence connecting NQO2 to p53 regulation remains tenuous and the
proposed mechanism by which this would be achieved is mostly implied from NQO1’s
known interactions with p53. There are further connections between NQO2 and cancer
beyond possible roles in p53 regulation. For instance, bladder and ovarian cancers have
been found to have increased expression of the protein and quinone reductase activity –
when NRH is supplemented to samples (51). A possible role for NQO2 in the prevention
of cancer has also been reported. Gaikwad et al. have reported that some products of
estrogen metabolism (estrogen ortho-quinones) act as substrates for NQO2 and can be
reduced by the enzyme (52). The 2-electron reduction of such estrogen derived molecules
may be beneficial as they can be reduced to semiquinones and contribute to the
carcinogenicity of both endogenous and exogenous estrogen compounds (53). The caveat
with such an observation is that the synthetic NQO2 co-substrate BNAH is required for
the reaction to proceed (52).
Utilizing NQO2 to activate prodrugs and treat cancers that have higher levels of
the enzyme compared to other cells remains a viable use of the protein’s potential to
perform quinone reductions. As mentioned, the drug CB1954 is being investigated for
such uses (39). A combined clinical and laboratory study published a decade ago by
Middleton et al. looked at a treatment protocol wherein patients – who possessed solid
tumors and for whom all standard treatments had proven ineffective – were infused via
IV with CB1954 and the nicotinamide derivative EP0152R (54). Ultimately the phase I
clinical trial was ended due to unacceptably high toxicity that was attributed largely to

15

CB1954 reduction in the liver – a result also observed in a prior trial of CB1954 (55). Of
the types of tumors examined in the study all had significantly higher expression of
NQO2 relative to comparable healthy tissues and biopsies after treatment indicated that
significant DNA cross-linking was occurring as a result of CB1954 reduction (54). The
adverse events observed in the study were attributed to interactions in the liver because,
although the tumors studied express relatively high levels of NQO2 compared to most
cells they had lower levels of NQO2 compared to liver. For that reason the authors
identified hepatocellular carcinomas as the best target for CB1954 treatment as NQO2 is
even more abundant in such cancers than it is in healthy liver cells and patients with such
tumors in the study had the fewest and least severe adverse events (54).

1.3.2

Signaling Roles for NQO2

1.3.2.1

NQO2 Identified as a Third Melatonin Binding Site

The first indication that NQO2 may be a melatonin binding site came from studies
examining 2-[125I]iodomelatonin interaction profiles in Syrian hamster brain and
peripheral organ tissues (56). At the time of the study the first two melatonin receptors
(mt1 and MT2 respectively) had already been identified in humans and have since been
well characterized as G Protein-Coupled Receptors (GPCR) (57,58,59). Paul et al.
characterized the binding of their melatonin analog in a variety of tissues and determined
that there appeared to be a third melatonin binding site with nanomolar affinity (rather
than the picomolar affinity of the first two receptors). Interestingly, they made the
prediction – based upon the binding kinetics and high rates of saturation in kidney and
intestine tissues – that the third melatonin binding site was likely an enzyme, suggesting
cytochrome P-450 as a candidate (56).

16

The prediction that MT3 was an enzyme would later be proven true by the same
group when they determined NQO2 matched the characteristics of MT3 (48). Using a
melatonin analog more specific for MT3 Nosjean et al. were able to purify the binding site
from Syrian hamster kidneys and determined the protein be 95% identical to human
NQO2. Subsequently human NQO2 was found to have characteristics consistent with
MT3 and was able to be purified from samples using the specific ligand for melatonin’s
third binding site (48). Compared to the two GPCRs that melatonin binds to, little is
known about how NQO2 contributes to melatonin’s effects. Structures of melatonin and
several analogs bound to NQO2 have been determined and mice with NQO2 knocked out
lose the characteristics of the MT3 binding site (60,61,62). Beyond the cited results there
are few answers as to the role NQO2 may play in melatonin signaling.
Research into the relationship between NQO2 and melatonin has yielded useful
tools for the study of NQO2 in other contexts. The NQO2 specific inhibitor S29434 was
developed out of the effort to find more potent and specific ligands for the MT3 binding
site. The compound inhibits NQO2 enzymatic activity with an IC50 value in the
nanomolar range and is an excellent tool for complementing kinetics studies of the
protein (63). Validation of the specificity of this compound for NQO2 – the only other
confirmed interactor being MT2 – and the ability for the compound to enter cells and
remain non-cytotoxic at concentrations below 10 mM opens the door for studying various
pathways within cells that may be altered upon inhibiting NQO2 with S29434 (64).
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1.3.2.2

Autophagy Mediated by NQO2 in Response to Oxidative
Stress

Aided by the development of the above mentioned S29434, the study of NQO2’s
relationship to oxidative stress (OS) has provided more insights into a biologically
relevant role for NQO2. One such study published in 2011 by Reybier et al. utilized
electron paramagnetic resonance to examine the redox cycle of both NQO2 and NQO1
given a variety of combinations of co-substrates, substrates and inhibitors (65). To
summarize their findings, both NQO2 and NQO1 generate a variety of oxidative
byproducts (among which are H2O2, radical hydroxyls, semiquinones and unstable
hydroquinones) regardless of the combinations of co-substrates and substrates used for
the respective enzymes. A finding that distinguishes the two enzymes is that when
catalase is added to the reaction mixtures of NQO1 radical production was abrogated. In
contrast when the same was done for NQO2 reactions, using NRH as substrate, peaks
corresponding to semiquinone intermediates were detectable (65). Although it remains
unclear if NRH is abundant enough in cells for NQO2 to efficiently utilize, this finding
suggests that if it were NQO2 may be prone to forming semiquinones or unstable
hydroquinones.
Further evidence of a connection between NQO2 and oxidative stress is
demonstrated by the ability of S29434 to rescue rats and cell cultures from death as a
result of ROS production from paraquat treatment (66). It does not seem that paraquat
was acting as either a substrate or inhibitor of NQO2 as evident by the NQO2 activity
assays performed in the study. The results also corresponded with an earlier study that
showed melatonin to be able to protect rats from paraquat (67). Given that melatonin is a
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far less potent inhibitor of NQO2 compared to S29434 the protection from OS is
probably not due to inhibiton of NQO2 enzymatic activity. Paraquat also appears not to
be a substrate of NQO2, suggesting that the OS it generates in cells is not modulated by
NQO2 enzymatic activity but rather some NQO2 mediated signaling event that can be
controlled by these molecules (63,66).
A later study by Janda et al. indicated that the relationship between NQO2 and
oxidative stress was connected to autophagy regulation (49). While examining long-term
OS (as a result of paraquat treatment) in astrocyte cultures it was found that lipidated
LC3 (LC3-II) was significantly reduced and autolysosomes had impaired formation. The
observation that other markers for the induction of autophagy were increased indicated
that paraquat was stalling the autophagic response mid-way through (49). NQO2 was
shown to be implicated in this response because cotreatment with S29434 and paraquat
alleviated the stalling of autophagic-flux and actually promoted the progression of the
autophagy pathway. Further, treating cells over expressing NQO2 with paraquat or
adding chloroquine to the treatment compounded the negative effects of OS and
impairment of autophagy (49). Thus, providing evidence for regulation of autophagy by
NQO2 and connecting NQO2 to the effects of chloroquine treatment.
A comprehensive evaluation of the NQO2 specific inhibitor S29434 published in
2019 further validated the role of NQO2 as an inhibitor of autophagic flux (64). In this
study a human liver cell line (HepG2) was examined when treated with S29434.
Similarly to the above mentioned study, S29434 promoted the accumulation of LC3-II.
The result in the HepG2 cells was observed without the exposure to OS (i.e. without
paraquat treatment), a result that was demonstrated as well in the study using astrocytes,
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suggesting ROS are not necessary for NQO2 to exhibit inhibition of autophagy (49,64).
Knocking down NQO2 also produced significant accumulation of LC3-II, thus
complementing the findings from S29434 treatment, providing further support that
NQO2 is regulating autophagy (64).

1.3.3

Extracellular Vesicle Function
A paper by Dorai et al. published in 2018 highlighted a potential role for NQO2

in large extracellular vesicle (LEV) formation and identified an unbeknownst protein
interactor. In a pull-down assay NQO2 was found to bind to caveolin-1 (CAV1), an
interaction predicted by molecular modeling to occur between one of two CAV1 binding
sites in NQO2 and the scaffolding portion of CAV1 (50). CAV1 plays a key role in the
formation of caveolae and their shuttling to the cell membrane, caveolae being vesicles
that facilitate the transport of molecules (such as lipids and proteins) both intracellularly
and extracellularly (68,69).
The study by Dorai et al. also utilized cell lines that model the progression of
prostate cancer (the LNCaP-C4-2B model developed by Thalmann et al.) from an
androgen dependent, to androgen independent, and ultimately cancer cells that will
metastasize to bone (70). In this model it was found that CAV1 expression gradually
increases in accordance with the progression of prostate cancer in this model, with the
greatest abundance in the metastatic line. NQO2 also gradually increases in expression
from the androgen dependent to the independent stages but drastically dropped off in the
final metastatic stage (50). The phenomenon was not due to lower expression of the
NQO2 transcript but because NQO2 had become associated with the membranes of LEV
as evident by the protein’s increased presence in the insoluble membrane fractions and
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excreted vesicles. Not only does this demonstrate that NQO2 under certain circumstances
can play roles in vesicle formation but also strongly suggests that NQO2 may be
important in the colonization of bone by metastatic prostate cancers (50).

1.4
Known Interactions of NQO2 with Drugs and other
Small Molecules
Both NQO1 and NQO2 have a wide variety of compounds that interact with the
respective proteins as either substrates or inhibitors. Though there are some similarities in
their interaction profile such as menadione being a substrate for both enzymes, the
differences are much more pronounced (21,71). For instance, dicoumarol is the reference
inhibitor for NQO1 and S29434 is the proposed reference inhibitor of NQO2 activity –
each of these compounds having little to no effect on the other enzyme (21,64). NQO2
also interacts with a wide range of clinical drugs and small molecules, an interaction
profile that seldomly overlaps with NQO1.
In some instances, the drugs that interact with NQO2 behave as substrates, such as the
aforementioned CB1954 or the commonly taken acetaminophen (39,72). DNAintercalating agents have also been identified as NQO2 interactors (73). The study of
several DNA-intercalators demonstrated that NQO2 could be inhibited with nanomolar
concentrations of ethidium bromide, acridine orange and doxorubicin. Ethidium bromide
and acridine orange were shown to have greater affinity for the reduced form of NQO2
and doxorubicin the oxidized form, demonstrating that compounds have a preference for
particular redox states of the enzyme (74). The interactions between NQO2 and small
molecules/drugs is important to understand as NQO2 may be contributing to their effects
as demonstrated by its relationship to paraquat and oxidative stress (66). Furthermore the
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competing modes of action of different NQO2 interactors, exemplified by the opposing
effects on autophagy of paraquat and melatonin analogs, indicates that NQO2 has
dynamic roles in regulation.
Kinase inhibitors are a class of drugs that have an unusual propensity to have NQO2
as an off-target interactor, the effect of such interactions being poorly understood (75).
Many of the drugs are clinically used to treat specific types of cancers such as chronic or
acute myelogenous leukemia (CML/AML), or cancer more broadly (5,76). What is
known about NQO2’s interactions with such drugs points towards NQO2 having a
contribution towards apoptosis or proliferation but much more robust investigation must
be done (77,78). The affinity between NQO2 and the identified kinase inhibitors is often
very high and would indicate interactions with NQO2 at clinical doses are possible,
necessitating a more thorough investigation into NQO2 dependent effects of such drugs.

1.4.1

Target of Antimalarial Drugs
Quinoline antimalarial drugs have been used to treat the deadly infection since

about the mid-point of the twentieth century (79). Though used extensively for decades
the fine details of the various drugs’ mechanism of action were not known beyond the
idea that they would combat Plasmodium falciparum sporozoites in the blood of the
human host. Protein targets for an array of antimalaria drugs, such as primaquine and
chloroquine, would not be identified until the early 2000s.
NQO2 and aldehyde dehydrogenase 1 (ALDH1) were identified by Graves et al.
as human encoded proteins that interact with chloroquine and primaquine in their 2002
study of the quinoline drugs (80). Proteins were identified initially by running red blood
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cell extracts infected with P. falciparum through an ATP-Sepharose column, wherein
NQO2 and ALDH1 were eluted upon passing the respective drugs through the column.
Surprisingly the drugs did not appear to interact with any P. falciparum proteins, the two
human enzymes being the only candidates (80). While ALDH1 was determined to be
poorly inhibited by the antimalarial drugs, NQO2 could be inhibited quite potently.
Furthermore, chloroquine and primaquine were demonstrated to have affinities for the
opposite states of the enzyme, i.e. chloroquine binds to reduced NQO2 preferentially
while primaquine is selective for the oxidized state (80,81).
The different binding preferences for primaquine and chloroquine point towards
different roles for NQO2 in the pharmacological action of the drugs. Crystallographic
structures have been determined for each of these drugs in complex with NQO2 and
illustrates the differences in their interaction with the enzyme. Both primaquine and
chloroquine interact with the active site of NQO2 in comparable configurations to other
ligands of the protein (6). The binding of chloroquine to the reduced state of NQO2
however, is coordinated by distinct features not observed in oxidized structures. Though
it appears subtle, an approximate 5° bend in the isoalloxazine ring of FAD is most
notable and seems to be responsible for the drastic change in the space group the
structure was solved in and leads to conformational changes in the protein (6). It remains
unclear how/if the conformational changes between the oxidized and reduced state of the
enzyme translates into biological action but does demonstrate a “switching” in the
structure is possible and may be responsible for signal transduction.
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1.4.2

CK2 Inhibitor Interactions
The drug 4,5,6,7-tetrabromobenzotriazole (TBB) is an inhibitor of casein kinase 2

(CK2), the inhibition of which promotes the apoptosis of cells (82). Further inhibitors
competitive for the ATP site of CK2 were derived based upon TBB, namely 4,5,6,7tetrabromobenzimidazole (TBBz), and 2-dimethylamino-4,5,6,7-tetrabromo-1Hbenzimidazole (DMAT), compounds which more potently and selectively inhibit CK2
(83,84). CK2 functions as a serine/threonine kinase and has been characterized as a major
driver in the development and progression of multiple cancers and is thus a promising
target for drug therapy, though supposedly specific drugs often have many off-target
interactors that may contribute to their effects (85).
Investigation into the CK2 independent effects of TBB, TBBz, and DMAT
demonstrated that TBBz and DMAT were both potent inducers of apoptosis in cells
expressing a CK2 mutant resistant to drug inhibition (78). TBB on the other hand exerted
its apoptotic effects predominantly through CK2 suggesting that TBBz and DMAT had
additional targets. In a chemoproteomics approach NQO2 was identified as being a
protein interactor with TBBz and DMAT, while it was not identified in the TBB screen
(78). Structural and kinetic investigation into NQO2’s relation to these CK2 inhibitors
revealed that TBB was a weak inhibitor of NQO2 enzymatic activity while TBBz and
DMAT could inhibit with nanomolar concentrations (86). The inhibition by TBBz occurs
through its binding the oxidized state of the enzyme while DMAT had about equal
preference for each redox state.
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1.4.3

Chemoproteomic Screens of Clinical Drugs
The mentioned CK2 inhibitors represent a portion of the kinase inhibitors

determined to bind to NQO2 with significant affinity. The protein kinase c (PKC)
inhibitor bisindolylmaleimide III (BisIII) was one of the earliest known kinase inhibitors
to bind to NQO2. This discovery was made in 2004 by Brehmer et al. where NQO2 was
one of about 40 protein targets to be purified from HeLa cell samples using BisIII
immobilized on a column, where it was notable for being the only non-kinase target (87).
The study also determined that BisIII was an inhibitor of NQO2 activity though it appears
to be less potent than subsequent kinase inhibitors identified as NQO2 interactors.
The revolutionary clinical kinase drug imatinib has been a great success story for
targeted cancer therapy. This drug, indicated primarily for CML treatment, inhibits the
tyrosine kinase BCR-Abl which results from the fusion of two genes and aggressively
promotes proliferation (5,88). Though remarkably effective, Imatinib resistance could be
developed in some cases which drove the development of additional BCR-Abl inhibitors
(nilotinib and dasatinib).
Coincidentally, two chemical proteomics papers looking at the interaction profiles
of these BCR-Abl inhibitors were published in 2007 (Bantscheff et al. and Rix et al.) and
both studies identified NQO2 as an off-target protein interactor (89,90). Imatinib,
dasatinib and bosutinib were analyzed by Bantscheff and colleagues using a kinobead
approach that found NQO2 to interact with imatinib but not the other kinase inhibitors –
whereas Rix and colleagues studied imatinib, dasatinib and nilotinib and used affinity
purification, via sepharose immobilized drugs, and observed that NQO2 binds to both
imatinib and nilotinib but not dasatinib. In both cases not only was imatinib determined
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to bind to NQO2 but was characterized as a nanomolar inhibitor of NQO2 activity,
making the drug capable of inhibiting NQO2 at the clinical concentrations used – given
that NQO2 could act as an enzyme under physiological conditions (89,90). Beyond what
was described in the two studies mentioned not much else is known about the NQO2imatinib interaction except for a paper publishing the crystal structure and further
validation of the kinetics (91).
Though little is known about how NQO2 contributes to the pharmacological
action of the kinase inhibitors it binds to, the interactions would seem to be more than
coincidence. A fact demonstrated when a chemical proteomics study of 243 clinical
kinase inhibitors found NQO2 to be an interacting protein with 34 of the drugs studied
(92). Most notable were the nanomolar interactors pacritinib (JAK2 and IRAK1
inhibitor), and crenolanib (FLT3 inhibitor). Another interesting NQO2 interactor was
sunitinib which already has approved uses for gastrointestinal stromal tumor treatment in
the event that imatinib fails as a treatment (93). While 34 of the clinical kinase inhibitors
bound to NQO2, none of them were noted to bind to NQO1 suggesting that NQO2 has a
peculiar affinity for kinase inhibitors (92).

1.4.4

Combination Therapy of Drugs that Interact with NQO2
The NQO2 interacting drug chloroquine was most prominently used as an anti-

malarial medication but is also notable for its ability to inhibit autophagy (94).
Chloroquine’s ability to inhibit autophagy has shown to have beneficial effects in the
treatment of some cancers and can enhance the effects of anticancer medications when
used in combination with them (95). The inhibition of autophagy by chloroquine has been
shown to cause cell death in glioblastoma cell lines that occurs irrespective of inducers of
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apoptosis (96). Combination treatment of chloroquine and tetrandrine has been studied in
a variety of cancer cell lines and was shown that this combination has a synergistic effect
on cytotoxicity of the drugs and ROS production in cells (97).
The fact that NQO2 is the only known protein to be affected by chloroquine at
clinical doses is interesting in and of itself (80). Chloroquine has also been used in
combination with other NQO2 interacting drugs in order to enhance the effects of
treatment with such drugs. The recently identified NQO2 interacting kinase inhibitor
sunitinib has been shown to act synergistically with chloroquine in cancer models
(92,98). Combination of these drugs led to a significant decrease in the tumor volume of
mice. Furthermore, sunitinib was shown to be inducing autophagy and chloroquine’s
inhibition of the latter stages of autophagy may be contributing to increased apoptosis in
cells (98). Li et al. demonstrated very similar results in their combined use of sunitinib
and chloroquine on renal cell carcinoma cell lines. In this study it was shown that cell
proliferation is significantly impacted by the treatment with both of these NQO2
interactors and also led to increased apoptosis – the use of a number of markers of
autophagy also indicates that though being induced, autophagy is stalled as evident by the
buildup of acidic vesicular organelles (99).
Imatinib treatment also appears to be enhanced with the use of chloroquine
through comparable mechanisms as sunitinib (100). The fact that both the drugs used in
the respective combinatorial treatments bind strongly to NQO2 would seem to implicate
the enzyme in the mechanism of action though no study has investigated the contribution
of NQO2 to the synergism of these drugs.
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1.5

Project Description/Goals

The basis of this thesis project is understanding how NQO2 contributes to the
effects of various drugs that have been identified as interactors for the enzyme. This was
accomplished with the use of HCT116 cell lines and HeLa cell lines that have had the
gene for the NQO2 protein knocked out. The HCT116ΔNQO2 cell lines were previously
generated by Kevin Leung as part of his thesis project on NQO2 and the HeLaΔNQO2 cells
were generated by Dr. Brian Shilton, the knockout of the NQO2 gene was achieved with
CRISPR/Cas9 (101/unpublished work). Toxicity assays were utilized to calculate the
IC50 values of various drugs and the responses of cells expressing NQO2 were compared
to those that no longer expressed the enzyme.
Kevin Leung found no significant differences between the HCT116 cell lines in
their response to the CK2 inhibtiors (TBB, TBBz, DMAT) or with several NQO2 binding
DNA chelators. The contribution of NQO2 to p53 regulation was also difficult to
determine and yielded mixed results (101). Further experiments on these cells was
warranted however as there are a wide range of compounds and kinase inhibitors that
bind to NQO2 that were not covered in that project. Several more kinase inhibitors were
utilized in this study in addition to the autophagy inhibitor chloroquine.
The HeLa cells were chosen because, the study by Duncan et al. used HeLa cells
in their study that identified NQO2 as an interactor with the aforementioned CK2
inhibitors (78). NQO2 may have effects that are cell line dependent thus, having
additional cell lines for study would allow for the identification of effects that might not
be seen in one cell line or the other. The effects of the CK2 inhibitors on the HeLa and
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HeLaΔNQO2 cell lines were investigated with toxicity assays and examining apoptosis.
Further, additional kinase inhibitors and chloroquine were also examined.
Previous work has elucidated the structures of NQO2 in complex with many of
the drugs utilized in this study (6,74,86,92). Solving these structures has provided
evidence to support a flavin-redox switch function for NQO2 based upon the changes that
occur in the conformation of NQO2 from the oxidized to reduced state and different
modes of drug binding between these two states (6). To this end x-ray crystal structures
for oxidized and reduced NQO2 in complex with sunitinib were solved to see if this
would reveal more insights into the modes of drug binding to the NQO2 enzyme.
Sunitinib was identified by Klaeger et al. as a micromolar interactor with NQO2, though
they solved the structures of NQO2 and several higher affinity kinase inhibitors they did
not do so with sunitinib (92). There is reason to believe that though sunitinib is a lower
affinity binder to oxidized NQO2 it may have stronger interactions with the reduced form
of the enzyme as shown with other drugs (6,86). Determining how various drugs bind to
NQO2 is important because, multiple modes of binding to the active site have been
identified and preferences for distinct redox states of NQO2 have been shown. These
modes of binding and different affinities may be governing how cells are affected and
could explain the varied effects of different drugs that bind to NQO2.
Label-free mass spectrometry was also utilized in this experiment to investigate
how knocking out NQO2 in cells affected the proteome. The HCT116NQO2+,
HCT1161ΔNQO2, and HCT1162ΔNQO2 cell lines were compared to one another and
identified extensive changes to the proteome that were mediated by the expression of
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NQO2. The results of this experiment provide ample avenues of further research and has
revealed new cellular mechanisms that mat be regulated by NQO2. Validation of the
mass spectrometry results with cellular studies are warranted. Further experiments should
also be conducted to see how treatment with NQO2 interacting drugs impacts the
proteome in the cell lines used in this study.
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Chapter 2 – Materials and Methods
Reagents

2

TBB, DMAT, Sulforhodamine B (SRB), 3-(4,5-dimethylthiozol-2-yl)2,5diphenyltetrazolium (MTT), 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (SCDP) and bovine serum albumin (BSA) were obtained from SigmaAldrich. Dulbecco's Modified Eagle Medium (DMEM), McCoy's 5A medium, TrypsinEDTA (0.25%), Heat-Inactivated fetal bovine serum (FBS) Trypan blue (0.4%), KH2PO4,
Dimethyl sulfoxide (DMSO), chloroquine, primaquine, and imidazole were bought from
Thermo-Fisher. The kinase inhibitors sunitinib, crenolanib, and pacritinib were bought
from MedChem Express. TBBz was obtained from Calbiochem. CB1954 was purchased
from MedKoo. Sodium dodecyl sulfate (SDS), ammonium persulfate, and TEMED were
from BioRad. Trichloroacetic acid (TCA) was bought from BDH. EDTA was from
OmniPur. Acetic acid obtained from Caledon Chemicals. NaCl, KCl, Na2HPO4, Tris,
HEPES, and (NH4)2SO4 were from EM Science. Penicillin-streptomycin was from
ATCC.

2.1

Cell Culture

HeLa and HeLaΔNQO2 cells were cultured with DMEM supplemented with 10%
FBS and 1% penicillin/streptomycin. HCT116NQO2+, HCT1161ΔNQO2, and HCT1162ΔNQO2
cells were cultured with McCoy’s 5A medium supplemented with 10% FBS and 1%
penicillin/streptomycin. All cells were cultured under 37°C with 5% CO2. When
changing media or lifting cells, plates were washed with PBS at least twice before adding
fresh media or trypsin-EDTA to detach cells. Cells were counted manually using a glass
hemocytometer under a microscope after staining with trypan blue, including only cells
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not stained with trypan blue in the count. The number of viable cells/mL of cell
suspension was calculated by taking the average cell count of 4 sets of squares on the
hemocytometer and multiplying by 104 to correct for volume, then multiplying by 5 to
correct for the 1:5 dilution of cell suspension with trypan blue.

2.2

Cell Proliferation Assay

The SRB assay method was used to determine proliferation rates of the HeLa and
HeLaΔNQO2 cell lines utilized in this study (102). The respective cell lines were seeded at
about 1,000 cells per well. Each day one row of each cell line (n=5 wells) was fixed to
the plate using 10% TCA and washed with water. At the end of the time course 0.3%
SRB dye (in 1% acetic acid) was added to each well, incubated at room temperature for
1hr, then washed with 1% (vol/vol) acetic acid. The SRB dye was then solubilized in 10
mM Tris base (pH 10.5), then placed on a shaker for 10 mins before measuring the
absorbance at 560 nm on a Victor multi-plate reader, Perkin Elmer.

2.3

MTT Assay for Drug Toxicity IC50 Determination

Cell sensitivity to various kinase inhibitors and other drugs was determined via
MTT assay (103). Generally, approximately 1,000 cells (unless otherwise stated) were
initially seeded per well in a 96 well plate. After attachment overnight fresh media
(appropriate for cell line being used) was mixed with respective drug/s at appropriate
concentrations and applied to cells (at least 3 wells for each treatment
concentration/condition were used or more where stated). Plates were incubated for
appropriate times at 37°C with 5% CO2. After time-course of the treatment, spent media
was aspirated and fresh media supplemented with 1 mg/ml MTT reagent (in PBS) was
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added to all wells and the plate incubated typically for 3-4.5hrs at 37°C. This solution
was aspirated and the formazan crystals that formed were dissolved in 50 µl of DMSO.
After incubating for 15 minutes plates were analyzed with a Victor multi-plate reader,
Perkin Elmer, reading absorbance at 560 nm. Background absorbance of MTT solution in
wells with no cells was subtracted from all values and treatment absorbances normalized
to respective cells with either no treatment or vehicle control. Data were plotted and
analyzed in Prism 8.4.2. (GraphPad Software Inc).

2.4

SRB Assay for Drug Toxicity IC50 Determination

Cell culturing and drug treatment was conducted the same as for the MTT assay.
After time-course of the treatment cells were fixed to the plate using 10% TCA and
washed with water multiple times, then dried thoroughly. 0.3% SRB dye (in 1% acetic
acid) was added to each well, incubated at room temperature for 1hr, then washed with
1% (vol/vol) acetic acid multiple times and dried. The SRB dye was then solubilized in
10 mM Tris base (pH 10.5), then placed on a shaker for 10 mins before measuring the
absorbance at 560 nm on a Victor multi-plate reader, Perkin Elmer. Background
absorbance of SRB dye in wells with no cells was subtracted from all values and
treatment absorbances normalized to respective cells with either no treatment or vehicle
control. Data were plotted and analyzed in Prism 8.4.2. (GraphPad Software Inc).

2.5
Apoptosis in HeLa Cells Measured via PARP
Cleavage
Cells were seeded (HeLa or HeLaΔNQO2) in 6-well plates. Once cells reached 80%
confluency one of TBB, TBBz or DMAT were applied at either 8 µM or 50 µM
concentration. Treatments were carried out for 24 hrs at which point the respective cells
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were collected as pellets, washed with PBS, and frozen at -20°C as a pellet. After
freezing, cells were lysed with lysis buffer containing 20 mM Tris (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1.0% Triton-X-100 and a mix of protease inhibitors – 1 mM PMSF,
7 µg/ml Pepstatin A, 20 µg/ml Leupeptin, and 2.9 145 µg/ml Aprotinin. Samples were
sonicated briefly, then incubated in the lysis buffer for 30 mins with light constant mixing
at 4°C. After lysis cellular debris was removed by centrifugation at 10,000g and 4°C.
Protein samples were resolved via SDS-PAGE then transferred to PVDF membranes
(Millipore Immobilon-FL). Membranes were blocked with 5% BSA in Tris-buffered
saline, 0.1% Tween 20 (TBST) overnight at 4°C. Primary antibody incubation included
an antibody for full-length and cleaved PARP (1:1000, rabbit, Cell Signaling
Technologies) and GAPDH (1:1000, mouse, Cell Signaling Technologies) in TBST,
incubation was conducted for 1hr at room temperature. Fluorescently labeled goat-antimouse (IRDye 680RD)/rabbit (IRDye 800CW) secondary antibodies (LI-COR
Biosciences) were utilized and visualization conducted on a LI-COR Biosciences
Odyssey. Chameleon Duo (LI-COR Biosciences) was used as a protein ladder for
detecting transfer efficiency and determining molecular weight in fluorescent images.
Image Studio™ Lite was used for image analysis (LI-COR Biosciences).

2.6
X-ray Crystallography for NQO2-Sunitinib
Structure Determination
NQO2 was purified as previously described (8). Briefly, His-tagged NQO2 was
expressed from pPro-NQO2 plasmid in E. coli BL21(DE3). After separating NQO2 from
cell lysates using columns with bound Ni2+ the His-tag was removed by cleavage with
TEV protease. An anion-exchange column was used to further purify NQO2. To
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reconstitute the protein with FAD, protein samples were supplemented with 10 µM FAD
and further purified using a 2.6 × 65-cm column of Superdex 200 (GE Healthcare) while
running buffer through the column that was also supplemented with 10 µM FAD.
Crystallization of NQO2 was achieved with a wide variety of conditions using
either MES (pH 5.5), Cacodylate (pH 6.5), Tris (pH 8.5), or Imidazole (pH 7.5) as a
buffer and ammonium sulphate as a precipitant. NQO2 was co-crystallized with either 1
mM or 2 mM sunitinib. Initial data collections and screening were performed at the
Macromolecular Crystallography Facility (Schulich, Western University). Three
candidate crystals (Table 1) were sent to Canadian Light Source (CLS) and data
collected on CMCF-ID (104).
Table 1: Conditions for Co-Crystallization of NQO2 with Sunitinib.
Purified NQO2 [≈20 mg/mL] was co-crystalized with the kinase inhibitor sunitinib under specified
conditions at 21°C. Crystallization and screening was performed at the Macromolecular Crystallography
Facility. Crystals were passed through specified soaks before a final soak with a cryoprotectant – 20%
glycerol, 2.0 M (NH4)2SO4, 0.1 M HEPES, pH 7.5 – and freezing in liquid nitrogen.
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Data processing and merging was performed using MOSFLM and Scala
respectively (105,106). Refinements were performed in PHENIX via molecular
replacement (107). PDB:4FGK with ligand manually removed was used as the starting
model for oxidized crystal structure refinements and PDB:4ZVK with ligand manually
removed was used as the starting model for reduced crystal structure refinements (6,74).
Sunitinib was fit to structures using the Ligand Fit program in PHENIX using the
identification code for the drug (B49) and fitting two copies of the ligand to the model
(108).

2.7

Label-free Mass Spectrometry

To prepare cells for mass spectrometry HCT116NQO2+, HCT1161ΔNQO2, and
HCT1162ΔNQO2 cells were seeded in respective 10 cm plates (n=5). Cells were cultured
until reaching about 80% confluency, at which point cells were collected, washed twice
with PBS, lifted from plates with Trypsin-EDTA (0.25%), and centrifuged at 1,000g to
pellet cells. Cell pellets were frozen at -80 ℃. Frozen cell pellets were resuspended in 8
M Urea, 50 mM ammonium bicarbonate (ABC), 10 mM DTT, 2% SDS and sonicated
with a probe sonicator (20×0.5s pulses; Level 1). Twenty-five µg of protein lysate, as
quantified by Pierce™ 660 nm Protein Assay (ThermoFisher Scientific), was reduced in
10 mM DTT for 25 minutes, alkylated in 100 mM iodoacetamide for 25 minutes in the
dark, followed by methanol precipitation as described previously (109). Protein pellet
was resuspended in 200 µL of ABC and subjected to a sequential digest first with 250 ng
of LysC (Wako Chemicals, USA) for 4 hours, then 500 ng of Trypsin/LysC (Promega)
for 16 hours, followed by 500 ng of Trypsin (Promega) for an additional 4 hours.
Digestions were incubated at 37 ℃ at 600 rpm with interval mixing (30 seconds mix, 2
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minutes pause) on a Thermomixer C (Eppendorf, cat# 2231000667). After the last
digestion, samples were acidified with 10% formic acid to pH 3-4 and centrifuged at
14,000g to pellet insoluble material.
Approximately 1 µg of peptide sample was injected onto a Waters M-Class
nanoAcquity HPLC system coupled to an Orbitrap Elite mass spectrometer
(ThermoFisher Scientific) operating in positive mode. Buffer A consisted of mass
spectrometry grade water with 0.1% formic acid and buffer B consisted of acetonitrile
with 0.1% formic acid (ThermoFisher Scientific). All samples were trapped for 5 min at a
flow rate of 5 mL/min using 99% buffer A and 1% buffer B on a Symmetry BEH C18
Trapping Column (5 mm, 180 mm x 20 mm, Waters). Peptides were separated using a
Peptide BEH C18 Column (130 A˚, 1.7 mm, 75 mm x 250 mm) operating at a flow rate
of 300 nL/min at 35℃ (Waters). Samples were separated using a non-linear gradient
consisting of 1%–7% buffer B over 1 min, 7%–23% buffer B over 179 min and 23%–
35% buffer B over 60 min, before increasing to 98% buffer B and washing. MS
acquisition settings are provided (Table 2).
Table 2: Mass Spectrometry Acquisition Settings
Instrument

Orbitrap Elite

Mass range

400-1450m/z

MS1 resolution (Orbitrap)

120K

MS1 AGC target

1E+06

MS1 Injection time
Lock mass

200ms
445.120025

MS2 detection

IT

MS2 scan rate

Rapid

MS2 AGC target

1E+04

MS2 injection time

50ms

Top N

20

Isolation width

2
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MS2 Activation
Normalized Collision Energy
Dynamic exclusion

CID
35
enabled

Minimum signal required

500

Exclusion duration

30s

Exclusion mass width low

0.5

Exclusion mass width high

1.5

Charge Exclusion

unassigned, 1, >8

All MS raw files were searched in MaxQuant version 1.5.8.3 using the Human
Uniprot database (reviewed only; updated May 2017 with 42,183 entries) (110,111).
Missed cleavages were set to 2, cysteine carbamidomethylation was set as a fixed
modification and Oxidation (M), N-terminal Acetylation (protein) and Deamidation (NQ)
were set as a variable modifications (max. number of modifications per peptide = 5),
peptide length ≥ 6. Protein and peptide FDR was left to 0.01 (1%) and decoy database
was set to revert. Match between runs was enabled and all other parameters left at
default.
Bioinformatics analysis was performed using Perseus (Version; 1.6.6.0). Briefly,
protein lists were loaded into Perseus and proteins identified by site, reverse and
contaminants were removed. Two-sample t-tests were performed between each cell line
groups, significant change was classified as being a greater than two-fold change in
expression between groups and a p-value < 0.05. Gene lists of significantly changed
proteins were further analyzed by enrichment analysis using FunRich (Version; 3.1.3)
and g:Profiler followed by Cytoscape (Version; 3.8.0) respectively (112,113,114).

2.8

Exosome Isolation

Exosomes were collected by ultracentrifugation as adapted from Théry et al.
(115). Plates of the HCT116 cell lines were grown to about 80% confluency then media
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was replaced with serum free media for 2 days. After this incubation the media was
collected and centrifuged at 1,000g to remove detached cells, supernatant was then
centrifuged at 10,000g to remove cellular debris. Samples were then frozen overnight,
thawed and centrifuged at 100,000g to pellet exosomes. Ultracentrifugation was done for
1hr using a Beckman Optima MAX Ultracentrifuge set to 4°C using an MLA 80 Fixed
Angle Rotor. Exosome pellets were resuspended in PBS. Samples were resolved by SDSPAGE then stained with 0.5 g/L CoomassieTM Brilliant Blue. Western blot was
performed as described above using the primary antibody for GAPDH and a primary
antibody for CD9 (1:500, rabbit, provided by Dr. Paul Walton). Incubation with primary
antibodies was conducted overnight at 4°C, the above mentioned fluorescent secondary
antibodies were utilized for detection and incubated with the blot for 1hr at room
temperature.

2.9

CD73 Expression in HCT116 Cells

HCT116NQO2+, HCT1161ΔNQO2, and HCT1162ΔNQO2 cells were cultured to 80%
confluency. The respective cells were collected as pellets, washed with PBS, and frozen
at -20°C as a pellet. After freezing, cells were lysed with lysis buffer containing 20 mM
Tris (pH 7.5), 150 mM NaCl, and a mix of protease inhibitors – 1 mM PMSF, 7 µg/ml
Pepstatin A, 20 µg/ml Leupeptin, and 2.9 145 µg/ml Aprotinin. Samples were sonicated
briefly, then incubated in the lysis buffer for 30 mins with light constant mixing at 4°C.
After lysis cellular debris was removed by centrifugation at 10,000g and 4°C. Protein
samples were resolved via SDS-PAGE then transferred to PVDF membranes (Millipore
Immobilon-FL). Membranes were blocked with 5% BSA in Tris-buffered saline, 0.1%
Tween 20 (TBST) for 1hr at room temperature. Primary antibody incubation included an
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antibody for CD73 (1:1000, rabbit, Cell Signaling Technologies) and GAPDH (1:1000,
mouse, Cell Signaling Technologies) in TBST, incubation was conducted overnight at
4°C. Fluorescently labeled goat-anti-mouse (IRDye 680RD)/rabbit (IRDye 800CW)
secondary antibodies (LI-COR Biosciences) were utilized and visualization conducted on
a LI-COR Biosciences Odyssey. Chameleon Duo (LI-COR Biosciences) was used as a
protein ladder for detecting transfer efficiency and determining molecular weight in
fluorescent images. Image Studio™ Lite was used for image analysis (LI-COR
Biosciences).

2.10

Colony Formation Assay for Sunitinib Treatment

Respective cell lines were seeded at an initial density of 300 cells per well in 6well plates. One day after seeding, fresh media supplemented with respective drug
concentrations was added to each well (3 wells for each drug concentration). Cells were
grown in treatment conditions for 10 days total with fresh media and drugs being
replenished on days 4 and 8. After treatment was complete media was removed, cells
washed several times with PBS, and stained with 0.5% methylene blue in methanol for 30
minutes. Once stained, plates were washed thoroughly with tap water and scanned using
a desktop HP photo scanner. Scanned images were analyzed in Clono-Counter and data
plotted in Prism 8.4.2. (GraphPad Software Inc) (116).
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Chapter 3 – Results

3

Summary
A variety of experimental approaches were utilized in this study with the aim of

identifying cellular functions for NQO2 beyond quinone reduction. The first approach
used was to investigate how NQO2 contributed to the effects of various NQO2
interacting drugs when cells were treated with such compounds. To this end cell survival
was measured via either MTT or SRB assays, IC50 values calculated and compared
between NQO2 expressing cells and cells with NQO2 knocked out. Apoptosis was also
assayed, through PARP cleavage, in the HeLa cell lines after treatment with CK2
inhibitors to determine the extent to which NQO2 influenced apoptosis.
Structural analysis of NQO2’s interactions with drugs has provided valuable
information and may be used to identify NQO2 mediated effects within cells. In this
thesis high resolution structures of purified NQO2 bound to sunitinib were solved. A
structure for this complex did not previously exist and was important to obtain as
different binding motifs have been observed depending upon the drug. X-ray crystal
structures of both oxidized and reduced NQO2-sunitinib have been solved and can inform
further study on how different types of NQO2-drug interactions influence the effects
observed in cells when treated with such drugs.
The use of label free mass spectrometry allowed for the characterization of the
proteomes of the HCT116 cell lines used in this study. The analysis of the proteomics has
revealed extensive differences between the NQO2 expressing and NQO2 knockout cells.
This data has identified several cellular functions which may be influenced by NQO2 and
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can be followed up in further studies. In addition, many specific proteins have been
identified that NQO2 may regulate or have an influence on. The mass spectrometry data
will allow for the design of other cellular studies and hypothesis testing for various
potential roles for NQO2. Prior to this study, evidence for regulatory/signaling roles for
NQO2 was sparse but can now be investigated with greater precision.

3.1 Characterization of HeLa and HeLaΔNQO2 Cells
The HCT116 cells used in this study were previously generated and characterized
by Kevin Leung in his thesis project (101). Beyond verification that NQO2 was
successfully knocked out, it was determined that HCT116ΔNQO2 cells had attenuated
proliferation rates and additionally showed that NQO2 activity was abolished through use
of the NQO2 specific substrate CB1954. The HeLaΔNQO2 cells used herein were generated
by Dr. Brian Shilton and gene knockout was confirmed (unpublished work). This study
followed up on the characterization of these cells by examining proliferation and NQO2
activity as was done with the HCT116 cell lines.

3.1.1

HeLa and HeLaΔNQO2 Proliferation
The proliferation of HeLa and HeLaΔNQO2 cells was determined via SRB assay

over an 8 day time-course with an initial seeding density of 1,000 cells per well in 96
well plates. HeLa cells plateaued after 4 days, reaching their maximum density, while
HeLaΔNQO2 cells did not level out until about the 6th day of growth (Figure 3). The rate of
proliferation in the 2nd and 3rd days is distinct, with the knock-out cells lagging. This
result is consistent with what was observed in the HCT116 cell lines (101).
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Figure 3: Proliferation of HeLa (

) and HeLaΔNQO2 (

) Cells via SRB Assay.

≈1,000 cells per well were seeded in a 96 well plate. Each day one row of cells was fixed with 10%
Trichloroacetic acid (n=5 for each cell line), washed, and allowed to dry. After 8 days, once all cells were
fixed to the plate, SRB dye was added, solubilized and the absorbance measured.

3.1.2

NQO2 Activity is Absent in HeLaΔNQO2 Cells; Addition of NRH
Required for NQO2 Activity in vitro
The CB1954 prodrug is an NQO2 specific substrate and can be used to confirm

NQO2 specific activity in cells. HeLa and HeLaΔNQO2 cells were cultured with varying
concentrations of CB1954 for 48hrs in media with 0 µM NRH or media supplemented
with 100 µM NRH. Activation of CB1954 into cytotoxic form (via nitro-reduction by
NQO2) only occurred in HeLa cells cultured in media with 100 µM NRH (Figure 4(a)).
HeLaΔNQO2 cells were unable to activate CB1954 even with the addition of NRH. The
IC50 values for CB1954 treatment in the HeLa cells was significantly different between
the 0 µM and 100 µM NRH groups, the addition of NRH greatly increasing susceptibility
of the cells to treatment (Figure 4(b)). The difference between the IC50 values of HeLa
and HeLaΔNQO2 cells as well as the difference between HeLaΔNQO2 cells cultured with
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either 0 µM or 100 µM NRH was determined to be not significant. The results suggest
that NRH is not present in HeLa cells and that NQO2 is not able to use NAD(P)H.

Figure 4: CB1954 Toxicity Mediated by NQO2 and Exogenous NRH.
a) Toxicity assay of HeLa cells cultured with either 0 µM ( ) or 100 µM NRH (
cultured with either 0 µM (

) or 100 µM NRH (

) and HeLaΔNQO2 cells

). Cells were treated with varying concentrations of

CB1954 for 48hrs. Approximately 1,000 cells were initially seeded per well and each treatment condition
has 3 wells (n=3). The % survival was calculated by normalizing the absorbance of MTT dye to cells from
each group treated with 0 µM CB1954. b) Table of calculated IC50 values for the respective conditions
with 95% confidence intervals displayed. Data was plotted and analyzed in Prism 8.4.2, statistical analysis
performed was an ordinary one-way ANOVA with Tukey post-hoc test (**** indicates P-value ≤ 0.0001)
(GraphPad Software Inc).
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3.2

HeLa Cell Response to CK2 Inhibitor Treatment

The CK2 inhibitors TBBz and DMAT have been identified as off-target interactors
with NQO2. The observation by Duncan et al. that these drugs also induce CK2
independent apoptosis points to a possible role for NQO2 in this effect (78). Previous
examination of the toxicity of these compounds in the HCT116 cell lines used in this
study found no significant differences between HCT116NQO2+ and HCT116ΔNQO2 cell
lines when they were exposed to the CK2 inhibitors. The IC50 values were not different
and thus NQO2 status in the cells was not an important determinant for cytotoxicity in
that cell line (101). Duncan et al. used HeLa cells to make their discovery therefore the
contribution of NQO2 to apoptosis may be cell line dependent and warranted that the
toxicity of these drugs be determined in our HeLa cell lines.

3.2.1

TBBz and DMAT Significantly More Toxic to HeLaΔNQO2 Cells
The IC50 values, for drug toxicity to cells, was determined for several CK2

inhibitors via MTT assay. Two of the drugs examined (TBBz and DMAT) have been
shown to interact with NQO2, while the third drug (TBB) does not. Cells were seeded
with an initial density of 1,000 cells per well (in a 96-well plate) and treatments with drug
were carried out for 48hrs. The curves of cell survival for HeLa and HeLaΔNQO2 cells
treated with TBB are very similar, (Figure 5(a)) indicating there is little difference in
their response to treatment. The calculated IC50 values for HeLa cells treated with TBB
is 200 µM and for the HeLaΔNQO2 cells it is 81.3 µM. Statistical analysis of these
calculated values showed that this difference is non-significant (Figure 5(b)).
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Treatment with the NQO2 interacting TBBz and DMAT elicited a major shift in
the fit survival curves between the HeLa and HeLaΔNQO2 cell lines (Figure 5(c,e)). The
IC50 value for TBBz treatment differed between the cell lines by about 6-fold, the
HeLaΔNQO2 cells being more sensitive. The difference for TBBz treatment is statistically
significant with a P-value ≤ 0.0001 (Figure 5(d)). DMAT treatment resulted in calculated
IC50 values with about a 15-fold difference. HeLaΔNQO2 cells were also more sensitive to
DMAT treatment and the difference is significant with a P-value ≤ 0.0001 (Figure 5(f)).
The CK2 inhibitors that bind to NQO2 had differential effects based on whether
or not NQO2 was expressed by the cells. HeLa cells that express NQO2 are more
resilient to treatment with TBBz and DMAT. Knocking out NQO2 led to greater
sensitivity to these drugs. Sensitivity to TBB treatment – which does not bind NQO2 –
was not altered by NQO2 status in cells.
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Figure 5: NQO2 Interacting CK2 Inhibitors are More Toxic to HeLaΔNQO2 Cells.
Kill curves of HeLa (

) and HeLaΔNQO2 (

) cells after 48hr treatment with varying concentrations of

respective CK2 inhibitors ((a) TBB, (c) TBBz, (e) DMAT). Approximately 1,000 cells were initially
seeded per well and each treatment condition has 3 wells (n=3). The % survival was calculated by
normalizing the absorbance of MTT dye to cells from each group treated with DMSO vehicle control. Bar
graph of calculated IC50 values for the respective conditions ((b) TBB, (d) TBBz, (f) DMAT) with 95%
confidence intervals depicted as error bars. Data was plotted and analyzed in Prism 8.4.2, statistical
analysis of the data consisted of an unpaired two-tailed t-test (**** indicates P-value ≤ 0.0001) (GraphPad
Software Inc).

3.2.2

Dose Dependent Effects on Apoptosis after CK2 Inhibitor
Treatment and Contribution of NQO2
Apoptosis was assayed in the HeLa cell lines through observation of PARP and

cleaved PARP levels in cells via western blot. HeLa and HeLaΔNQO2 cells were treated
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with either 8 or 50 µM TBB, TBBz, or DMAT over a time period of 24 hrs. Treatment
samples were resolved by SDS-PAGE, transferred to a membrane and probed for with
antibodies for GAPDH and PARP/cleaved PARP. Levels of GAPDH were comparable
across treatment conditions and cell lines except for treatment with DMAT in the
HeLaΔNQO2 cell lines where GAPDH levels were noticeably lower (Figure 6(a)).

In the TBB treatment conditions PARP and cleaved PARP levels were very low.
Examining the ratios of cleaved PARP to PARP in such conditions showed that the levels
of PARP were higher in both cell lines and with both treatment doses (Figure 6(b)).
When cells were treated with TBBz the ratio of cleaved PARP to PARP was shifted
towards the cleaved protein. In HeLa cells the ratio was approximately the same when
cells were treated either with 8 µM or 50 µM doses of the drug. Not only were HeLaΔNQO2
cells more apoptotic under such conditions but the ratio of cleaved PARP:PARP
increased when the dose was increased (Figure 6(b)). DMAT was the most potent
inducer of apoptosis in the respective cell lines. At 8 µM dose of DMAT in HeLa cells
the ratio of cleaved PARP to PARP was 3.64, a value that increased to 6.76 at a dose of
50 µM. HeLaΔNQO2 cells treated with 8 µM DMAT were most apoptotic with a cleaved
PARP to PARP ratio of 8.59, this ratio decreased to 5.15 when 50 µM DMAT was
administered for 24 hrs (Figure 6(b)).
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Figure 6: CK2 Inhibitors Induce Apoptosis in a Dose Dependent Manner;
HeLaΔNQO2 Cells more Sensitive to Treatment Conditions.
Western blot for PARP and cleaved PARP as a marker for apoptosis (a). HeLa and HeLaΔNQO2 cells were
seeded in 6-well plates and cultured until reaching 80% confluency. Cells were treated with either 8 µM or
50 µM of TBB, TBBz or DMAT. Treatments were conducted for 24hrs at which point cells were collected
and samples prepared for western blotting. Signal for PARP and cleaved PARP (b) were normalized to
GAPDH and ratio of Cleaved PARP:PARP was plotted for the respective cells lines (HeLa (
HeLaΔNQO2 (

3.3

) or

)).

Chloroquine Co-Treatment with CK2 Inhibitors

A significant difference in the IC50 values of HeLa and HeLaΔNQO2 cells when treated
with TBBz or DMAT was observed. Previous work showed that there was no difference
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between HCT116 and HCT116ΔNQO2 cells when they were treated with CK2 inhibitors.
Chloroquine was selected to use in conjunction with the CK2 inhibitors to see if it would
elicit a more pronounced effect in the HeLa cells but also to test if it would produce a
noticeable phenotype in the HCT116 cells.
As mentioned, chloroquine’s ability to inhibit autophagy has been exploited to
attempt to enhance the toxicity of drugs (95,97,98). Chloroquine also interacts with
NQO2 – which is one of two human proteins known to bind chloroquine – and has
previously been studied in our lab for that reason (6,80). Investigation into the structure
of the NQO2-chloroquine complex revealed that chloroquine binds to reduced NQO2
preferentially and the complex has notable conformational differences from oxidized
NQO2 (6). The relationship between NQO2 and chloroquine is consistent with the
hypothesis that NQO2 functions as a flavin-redox switch and chloroquine may be an
“activator” of a switching function in NQO2. To that end adding chloroquine to the
treatment conditions with CK2 inhibitors may exacerbate NQO2 dependent effects.

3.3.1

HeLa Cell Treatment with CK2 Inhibitors and Chloroquine
Increases Toxicity of NQO2 Interacting Drugs
Chloroquine was administered at a constant concentration of either 0 or 20 µM

and kill curves for each CK2 inhibitor were generated under the respective conditions for
the respective cell lines. Treatments were conducted for 48hrs with an initial seeding
density of 2,000 cells per well. It is noteworthy that increasing the initial seeding density
to 2,000 from 1,000 (as done in Figure 5) lead to lower IC50 values for comparable
conditions thus, indicating cells were more sensitive to treatment at greater densities.
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As before (see Figure 5(a)) treating HeLa and HeLaΔNQO2 cells with TBB yielded
overlapping curves when 0 µM chloroquine was administered (Figure 7(a)). Applying 20
µM chloroquine lead to a slight increase in toxicity of TBB in HeLa cells but not
HeLaΔNQO2 cells. Analysis of the calculated IC50 values (Figure 7(b)) showed no
statistical significance between the groups or treatment conditions.
A significant difference was observed in the fit curves for TBBz treatment with 0
µM chloroquine between the HeLa and HeLaΔNQO2 cells (Figure 7(c,d)). When 20 µM
chloroquine was used to sensitize cells the IC50 value was significantly decreased in the
HeLa cells relative to the 0 µM condition. The differences in the IC50 values for
HeLaΔNQO2 cells treated with TBBz under the 0 and 20 µM conditions was determined to
be not significant. A comparison of the two cell lines under the 20 µM chloroquine
conditions revealed that the cells still expressing NQO2 were significantly more sensitive
to combined treatment with TBBz.
Under the DMAT treatment conditions a comparison between cell lines for both
the 0 and 20 µM chloroquine curves showed no statistical difference in their sensitivity to
DMAT (Figure 7(e,f)). A comparison within the respective cell lines showed that adding
20 µM chloroquine significantly decreased the calculated IC50 values for both cell lines.
This indicates that both cell lines were sensitized by chloroquine to DMAT exposure.
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Figure 7: Chloroquine Sensitizes HeLa Cells to TBBz and DMAT Treatment.
Kill curve of HeLa ( ) and HeLaΔNQO2 (

) cells after 48hr treatment with varying concentrations of

respective CK2 inhibitors ((a) TBB, (c) TBBz, (e) DMAT) and either 0 µM (Circle) or 20 µM (Square)
chloroquine. Approximately 2,000 cells were initially seeded per well and each treatment condition has 3
wells (n=3). The % survival was calculated by normalizing the absorbance of MTT dye to cells from each
group treated with DMSO vehicle control. Bar graph of calculated IC50 values for the respective
conditions ((b) TBB, (d) TBBz, (f) DMAT) with 95% confidence intervals depicted as error bars. Data was
plotted and analyzed in Prism 8.4.2, statistical analysis performed was a two-way ANOVA with Tukey
post-hoc test (* indicates P-value ≤ 0.05, ** indicates P-value ≤ 0.01, *** indicates P-value ≤ 0.001, ****
indicates P-value ≤ 0.0001, if comparison not displayed relationship is ns) (GraphPad Software Inc).
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3.3.2

HCT116 Cells Not Sensitized to CK2 Inhibitor Treatment by
Chloroquine
Toxicity assays for the CK2 inhibitors TBB, TBBz and DMAT were previously

performed by Kevin Leung in his thesis (101). HCT116NQO2+ cells and HCT116ΔNQO2
cells exhibited comparable levels of sensitivity to the drugs. This study followed up with
similar experiments utilizing chloroquine in combination with the drugs. Cells were
treated with respective CK2 inhibitors and either 0 or 10 µM chloroquine. Each cell line
was seeded at a density of 1,000 cells per well and treatment was carried out for 48hrs.
When treated with a range of concentrations for TBB and 0 µM chloroquine
HCT116NQO2+, HCT1161ΔNQO2 and HCT1162ΔNQO2; IC50 values were calculated to be
127.4 µM, 139.9 µM, and 250.8 µM respectively (Figure 8). Treating these cells with
TBB in combination with 10 µM chloroquine yielded IC50 values of 154.1 µM, 114.9
µM, and 117.8 µM. There was no significant difference in these values between cell lines
or between treatment groups.
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Figure 8: TBB Toxicity is not Dependent upon NQO2 Status in HCT116 Cells,
Chloroquine has no Sensitizing Effect.
Kill curve of HCT116NQO2+ (a), HCT1161ΔNQO2 (b), and HCT1162ΔNQO2 (c) cells after 48hr treatment with
varying concentrations of TBB and either 0 µM (

) or 10 µM (

) chloroquine. Approximately 1,000

cells were initially seeded per well and each treatment condition has 3 wells (n=3). The % survival was
calculated by normalizing the absorbance of MTT dye to cells from each group treated with DMSO vehicle
control. d) Bar graph of calculated IC50 values for the respective conditions with 95% confidence intervals
depicted as error bars. Data was plotted and analyzed in Prism 8.4.2, statistical analysis performed was a
two-way ANOVA with Tukey post-hoc test (GraphPad Software Inc).

Survival curves for HCT116 cell exposure to TBBz without any chloroquine
treatment are comparable between the cell lines used for this study (Figure 9(a,b,c)).
IC50 values for the treatment conditions are 23.9 µM, 22.5 µM, and 38.4 µM
(respectively for HCT116NQO2+, HCT1161ΔNQO2, and HCT1162ΔNQO2) and are not
significantly different (Figure 9(d)). Adding 10 µM chloroquine to the treatment
conditions increased cell sensitivity to TBBz slightly with calculated IC50 values of 7.05
µM, 11.4 µM, and 11.6 µM though the differences within respective cell lines was nonsignificant.
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Figure 9: TBBz Toxicity is not Dependent upon NQO2 Status in HCT116 Cells,
Chloroquine has no Sensitizing Effect.
Kill curve of HCT116NQO2+ (a), HCT1161ΔNQO2 (b), and HCT1162ΔNQO2 (c) cells after 48hr treatment with
varying concentrations of TBBz and either 0 µM (

) or 10 µM (

) chloroquine. Approximately 1,000

cells were initially seeded per well and each treatment condition has 3 wells (n=3). The % survival was
calculated by normalizing the absorbance of MTT dye to cells from each group treated with DMSO vehicle
control. d) Bar graph of calculated IC50 values for the respective conditions with 95% confidence intervals
depicted as error bars. Data was plotted and analyzed in Prism 8.4.2, statistical analysis performed was a
two-way ANOVA with Tukey post-hoc test (GraphPad Software Inc).

Exposure to DMAT for 48hrs yielded IC50 values of 58.2 µM, 39.6 µM, and 71.3
µM that were calculated from the curves for HCT116NQO2+, HCT1161ΔNQO2 and
HCT1162ΔNQO2 respectively (Figure 10(a,b,c)), statistical analysis of these values
showed there was no significant difference between these values (Figure 10(d)). When
chloroquine was also administered with DMAT at a constant concentration of 10 µM, the
IC50 values decreased to 13.9 µM, 12.8 µM, and 9.1 µM. Though the fold change in
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IC50 values is between 3-8 when comparing the values for 0 µM and 10 µM chloroquine
treatment with the same cell line, the difference is not significant due to the variance of
the data. No significant difference exists in these data sets between cell lines or between
treatment conditions.

Figure 10: DMAT Toxicity is not Dependent upon NQO2 Status in HCT116 Cells,
Chloroquine has no Sensitizing Effect.
Kill curve of HCT116NQO2+ (a), HCT1161ΔNQO2 (b), and HCT1162ΔNQO2 (c) cells after 48hr treatment with
varying concentrations of DMAT and either 0 µM (

) or 10 µM (

) chloroquine. Approximately 1,000

cells were initially seeded per well and each treatment condition has 3 wells (n=3). The % survival was
calculated by normalizing the absorbance of MTT dye to cells from each group treated with DMSO vehicle
control. d) Bar graph of calculated IC50 values for the respective conditions with 95% confidence intervals
depicted as error bars. Data was plotted and analyzed in Prism 8.4.2, statistical analysis performed was a
two-way ANOVA with Tukey post-hoc test (GraphPad Software Inc).
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3.4
Sunitinib Toxicity to Cells and Modulation by
Chloroquine
Several papers have reported that chloroquine treatment enhances the toxicity of
sunitinib. One paper demonstrated the effect in cancer cell lines, showing that using
chloroquine as sensitizer to sunitinib treatment increases the drug’s toxicity when
measured with proliferation assays (99). Another paper identified the synergistic effect
the drugs have on reducing tumor volume in mice (98). Chloroquine has been known to
bind to NQO2 since the 2002 study published by Graves et al. and sunitinib has been
more recently identified as an NQO2 binder in the Klaeger et al. study published in 2017
(80,92). The two papers referenced for combined chloroquine and sunitinib effects were
published in 2018 and 2014 respectively; neither considered the possible contribution of
NQO2 to the effects of either of the drugs. This study utilized the HeLa and HCT116
NQO2 knockout lines that have been generated to test the toxicity of these drugs when
used in combination. The aim was to test the extent to which NQO2 mediated the
combined effects of these drugs.

3.4.1

Cell Survival Curves for Sunitinib Treatment in Combination
with Chloroquine
The HeLa and HCT116 cell lines in this study were each subjected to toxicity

assays with varying doses of sunitinib in combination with chloroquine and cell survival
was determined via MTT assay. HeLa and HeLaΔNQO2 cells were seeded at 1,000 cells per
well and treated for 48hrs with a range of sunitinib concentrations and either 0, 0.5, or 5
µM chloroquine. HCT116NQO2+, HCT1161ΔNQO2 and HCT1162ΔNQO2 cells were seeded at
1,000 cells per well and treated for 48hrs with a range of sunitinib concentrations and
either 0, 2, or 10 µM chloroquine.
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HeLa cells treated with sunitinib and 0 µM chloroquine were determined to have
an IC50 value of 5.3 µM while HeLaΔNQO2 cells under the same treatment conditions had
an IC50 value of 4.3 µM (Figure 11(a,b)). The differences between these IC50 values
was determined to be non-significant (Figure 11(c)). Treating cells with 0.5 µM or 5 µM
chloroquine did not appreciably change either cell line’s susceptibility to sunitinib and
there was no statistical difference between cell lines or treatment conditions.

Figure 11: Chloroquine does not Sensitize HeLa Cells to Sunitinib Treatment.
Cell survival curve of HeLa (a) and HeLaΔNQO2 (b) cell lines respectively after 48hr treatment with a range
of concentrations of sunitinib and either 0 µM (

), 0.5 µM (

), or 5 µM (

) chloroquine.

Approximately 1,000 cells were initially seeded per well and each treatment condition has 3 wells (n=3).
The % survival was calculated by normalizing the absorbance of MTT dye to cells from each group treated
with DMSO vehicle control. c) Bar graph of calculated IC50 values for the respective conditions with 95%
confidence intervals depicted as error bars. Data was plotted and analyzed in Prism 8.4.2, statistical
analysis performed was a two-way ANOVA with Tukey post-hoc test (GraphPad Software Inc).
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Sunitinib treatment of HCT116 cell lines showed an increasing sensitivity to
sunitinib as the concentration of chloroquine was increased as measured by the calculated
IC50 values from the curve for cell survival (Figure 12(a,b,c)). Comparing the IC50
values for sunitinib treatment between the cell lines revealed a significant difference
between HCT116NQO2+ and HCT1161ΔNQO2 when no chloroquine was given to cells, with
HCT1161ΔNQO2 being more sensitive (Figure 12(d)). There was no difference between
HCT116NQO2+ and HCT1162ΔNQO2 or HCT1161ΔNQO2 and HCT1162ΔNQO2. When 2 µM
chloroquine was applied with sunitinib the IC50 value of each cell line was
indistinguishable from one another. When combined with a dose of 10 µM chloroquine,
both NQO2 knockout cell lines were significantly more sensitive to sunitinib than
HCT116NQO2+ was and were not significantly different from one another. Examining the
response to sunitinib treatment within cell lines demonstrates that each cell line was
significantly more sensitive when 10 µM chloroquine was administered in conjunction
with sunitinib than when 0 µM was given (Figure 12(e)). HCT116NQO2+ and
HCT1162ΔNQO2 were also more sensitive to chloroquine when given 2 µM chloroquine.
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Figure 12: Sunitinib Toxicity is Significantly Affected by NQO2 Status in HCT116
Cells Exposed to 10 µM Chloroquine; Sensitizing Effect Observed Across Cell
Lines.
Kill curve of HCT116NQO2+ (a), HCT1161ΔNQO2 (b), and HCT1162ΔNQO2 (c) cells after 48hr treatment with
varying concentrations of sunitinib and either 0 µM (

), 2 µM (

), or 10 µM (

) chloroquine.

Approximately 1,000 cells were initially seeded per well and each treatment condition has 12 wells (n=12).
The % survival was calculated by normalizing the absorbance of MTT dye to cells from each group treated
with DMSO vehicle control. Bar graph of calculated IC50 values for the respective conditions with 95%
confidence intervals depicted as error bars, grouped by either chloroquine concentration (d) or cell line (e).
HCT116NQO2+ (

), HCT1161ΔNQO2 (

), and HCT1162ΔNQO2 (

). Data was plotted and analyzed in

Prism 8.4.2, statistical analysis performed was a two-way ANOVA with Tukey post-hoc test (* indicates Pvalue ≤ 0.05, ** indicates P-value ≤ 0.01, *** indicates P-value ≤ 0.001, **** indicates P-value ≤ 0.0001,
if comparison not displayed relationship is ns) (GraphPad Software Inc).

3.4.2

Determination of Combination Index for Sunitinib and
Chloroquine Co-Treatment
In order to better characterize the relationship for the combined treatment of

sunitinib and chloroquine the combination index of these drugs was calculated. As
described by Chou and Talalay, the combination index which can be calculated for two or
more drugs allows one to determine whether co-treatment leads to synergistic, additive or
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antagonistic effects (Equation 1) (117,118). To make such calculations the toxicity of
sunitinib, chloroquine, and sunitinib:chloroquine were determined for 48hr and 72hr
treatment of the HCT116 cell lines, determined via SRB assay.
Equation 1: Combination Index Equation for Drug-Interaction Determination.
d1 and d2 are concentrations used in combination treatment for respective drugs to produce a set response
value (i.e. IC50 value). D1 and D2 are concentrations used to produce a set response value when the
respective drug is administered on its own. A CI value greater than 1 indicates antagonism, CI equal to 1
denotes additive effects and an CI value less than one indicates synergism between the drugs.

For 48hr treatment sunitinib, chloroquine and equimolar concentrations of
sunitinib and chloroquine were administered to HCT116NQO2+, HCT1161ΔNQO2, and
HCT1162ΔNQO2 cells. When sunitinib was administered alone there was no significant
difference between the calculated IC50 values of the cell lines, 5.4 µM, 5.5 µM, and 5.9
µM respectively (Figure 13(a,b)). Chloroquine when administered alone had IC50 values
of 29.6 µM, 45.2 µM, and 46.8 µM respectively for HCT116NQO2+, HCT1161ΔNQO2, and
HCT1162ΔNQO2 cells. The difference between HCT116NQO2+ cells and each of the
knockout cell lines was significantly different and the knockout cell lines were not
different from one another in their susceptibility to chloroquine (Figure 13(c,d)).
Treating cells with equimolar sunitinib and chloroquine had comparable results to
sunitinib treatment, with IC50 values of 5.3 µM, 4.9 µM, and 5.9 µM for the respective
cell lines (Figure 13(e,f)).
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Figure 13: Sunitinib Toxicity is Not Significantly Affected by NQO2 Status in
HCT116 Cells, NQO2 Expressing HCT116 Cells Significantly More Sensitive to
Chloroquine.
Cell survival curve of HCT116NQO2+ (

), HCT1161ΔNQO2 (

), and HCT1162ΔNQO2 (

) cells after 48

hour treatment with varying concentrations of sunitinib (a), chloroquine (c), or equimolar
sunitinib:chloroquine (e). Approximately 1,000 cells were initially seeded per well and each treatment
condition has 6 wells (n=6). The % survival was calculated by normalizing the absorbance of SRB dye to
cells from each group treated with DMSO vehicle control. Bar graph of calculated IC50 values for the
respective conditions (b,d,f) with 95% confidence intervals depicted as error bars. Data was plotted and
analyzed in Prism 8.4.2, statistical analysis performed was an ordinary one-way ANOVA with Tukey posthoc test (* indicates P-value ≤ 0.05, ** indicates P-value ≤ 0.01, *** indicates P-value ≤ 0.001, ****
indicates P-value ≤ 0.0001, if comparison not displayed relationship is ns) (GraphPad Software Inc).
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Using the calculated IC50 values from each treatment condition a CI value was
calculated for each cell line. HCT116NQO2+ has a CI of 1.15, a value that indicates a slight
antagonism using Chou’s criteria for examining CI values (118). Sunitinib and
chloroquine were found to have a CI value of 1.01 when HCT1161ΔNQO2 cells are treated
and indicates and additive effect. A slightly antagonistic effect was also observed for
HCT1162ΔNQO2 cells (summarized in Equation 2).

Equation 2: Sunitinib:Chloroquine Treatment has Antagonistic Effects in
HCT116NQO2+ and HCT1162ΔNQO2 Cells and a Nearly Additive Effect in
HCT1161ΔNQO2 Cells When Treated for 48hrs.

HCT116 cells were also subjected to sunitinib, chloroquine and
sunitinib:chloroquine treatment for 72hrs and toxicity to treatment determined via SRB
assay. Treatment with varying concentrations of sunitinib alone yielded a significant
difference between the IC50 values of HCT116NQO2+ (10.8 µM) and HCT1161ΔNQO2 (12.0
µM) with the former being more sensitive. HCT1162ΔNQO2 (11.4 µM) cells were not
significantly different in their response to sunitinib compared to the other two cell lines
(Figure 14(a,b)). All cell lines had significantly different IC50 values from one another
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when treated with chloroquine alone for 72hrs. HCT116NQO2+ was most sensitive,
HCT1161ΔNQO2 was intermediate and HCT1162ΔNQO2 was the most resistant cell line
(IC50 values were 58.2 µM, 68.5 µM, and 74.6 µM respectively) (Figure 14(c,d)). A
similar trend was observed from the survival curves for equimolar sunitinib and
chloroquine treatment where calculated IC50 values were 7.6 µM, 8.4 µM, and 9.3 µM –
with a significant difference between each cell line.
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Figure 14: HCT116ΔNQO2 Cells are Less Sensitive to Chloroquine Treatment.
HCT116 Cells that Express NQO2 More Sensitive to Combination Sunitinib and
Chloroquine Treatment.
Cell survival curve of HCT116NQO2+ (

), HCT1161ΔNQO2 (

), and HCT1162ΔNQO2 (

) cells after 72

hour treatment with varying concentrations of sunitinib (a), chloroquine (c), or equimolar
sunitinib:chloroquine (e). Approximately 1,000 cells were initially seeded per well and each treatment
condition has 8 wells (n=8). The % survival was calculated by normalizing the absorbance of SRB dye to
cells from each group treated with DMSO vehicle control. Bar graph of calculated IC50 values for the
respective conditions (b,d,f) with 95% confidence intervals depicted as error bars. Data was plotted and
analyzed in Prism 8.4.2, statistical analysis performed was an ordinary one-way ANOVA with Tukey posthoc test (* indicates P-value ≤ 0.05, ** indicates P-value ≤ 0.01, *** indicates P-value ≤ 0.001, ****
indicates P-value ≤ 0.0001, if comparison not displayed relationship is ns) (GraphPad Software Inc).
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CI values were calculated from the IC50 values of each treatment condition.
According to Chou’s criteria, moderate synergism (CI = 0.83) was observed in
HCT116NQO2+ cells when co-treated with sunitinib and chloroquine for 72hrs (118). The
same CI value was calculated for HCT1161ΔNQO2 cells. A nearly additive effect was
observed for HCT1162ΔNQO2 cells (summarized in Equation 3).
Equation 3: Sunitinib:Chloroquine Treatment Exhibits Moderate Synergism in
HCT116NQO2+ and HCT1161ΔNQO2 Cells and a Nearly Additive Effect in
HCT1162ΔNQO2 Cells Treated for 72hrs.

3.5
NQO2 Interacting Clinical Kinase Inhibitor Toxicity
to Cells Determined via SRB Assay
Toxicity of several clinical kinase inhibitors, identified by Klaeger et al. as NQO2
interactors, were assayed for toxicity in our cancer cell lines by SRB assay (92).
Crenolanib and pacritinib had the highest affinity for NQO2 of the clinical drugs assayed
in the afore mentioned study, each binding to NQO2 at nanomolar concentrations. The
HeLa cell lines in this study were treated for 48hrs with crenolanib, pacritinib, or
sunitinib and the HCT116 cell lines were treated for 18hrs with the same drugs. The
contribution of NQO2 to the toxicity of these drugs was examined through comparing the
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response of NQO2 knockout cell lines with the comparable cell lines that express the
enzyme.

3.5.1

NQO2 Contribution to Toxicity of Clinical Kinase Inhibitor
Drugs in HeLa Cell Lines
Cell survival assay was performed by initially seeding either HeLa or HeLaΔNQO2

cells at a density of 1,000 cells per well in a 96-well plate. After attaching to the plates,
cells were administered either crenolanib, pacritinib, or sunitinib at varying
concentrations for 48hrs. Pacritinib was the most toxic drug to both cell lines with IC50
values of 403 nM and 340 nM respectively for HeLa and HeLaΔNQO2 cells with no
significant difference between these responses (Figure 15(a,b)). Both cell lines also
responded to crenolanib treatment without a statistically significant difference between
their calculated IC50 values (2.6 µM and 2.7 µM) (Figure 15(c,d)). When treated with
sunitinib it was observed that HeLaΔNQO2 cells are significantly less sensitive (IC50 = 3.5
µM) to the drug when compared to HeLa cells (IC50 = 2.6 µM) (Figure 15(e,f)).
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Figure 15: NQO2 Interacting Clinical Kinase Inhibitors Crenolanib and Pacritinib
Equally Cytotoxic to HeLa and HeLaΔNQO2 Cells, Sunitinib More Toxic in Cells that
Express NQO2.
Kill curve of HeLa (

) and HeLaΔNQO2 (

) cells after 48hr treatment with varying concentrations of

kinase inhibitors pacritinib (a), crenolanib (c), and sunitinib (e). Approximately 1,000 cells were initially
seeded per well and each treatment condition has 8 wells (n=8). The % survival was calculated by
normalizing the absorbance of SRB dye to cells from each group treated with DMSO vehicle control. Bar
graph of calculated IC50 values for the respective conditions (b, d, f) with 95% confidence intervals
depicted as error bars. Data was plotted and analyzed in Prism 8.4.2, statistical analysis of the data
consisted of an unpaired two-tailed t-test (*** indicates P-value ≤ 0.001) (GraphPad Software Inc).
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3.5.2

NQO2 Contribution to Toxicity of Clinical Kinase Inhibitor
Drugs in HCT116 Cell Lines
HCT116 cell toxicity had been determined for sunitinib treatment at 48hr and

72hr timepoints. The IC50 values calculated after 72hr treatment was nearly twice as high
for each cell line when compared to 48hr treatment (see Figure 13,14). Toxicity of
sunitinib at an 18hr timepoint was determined along with the IC50 values of crenolanib
and pacritinib. Pacritinib had the lowest IC50 value of the kinase inhibitors across all cell
lines. HCT116NQO2+ had an IC50 value of 11.2 µM, the NQO2 knockout cell lines were
nearly twice as sensitive to the drug with respective IC50 values of 5.8 µM, and 6.5 µM.
The differences between the NQO2 expressing cell line and each of the knockouts was
statistically significant (Figure 16(a,b)). Treatment with crenolanib for 18hrs resulted in
no significant difference between HCT116NQO2+, HCT1161ΔNQO2, and HCT1162ΔNQO2
cells, with respective IC50 values of 30.7 µM, 25.8 µM, and 28.3 µM (Figure 16(c,d)).
When treated with sunitinib for 18hrs, HCT1161ΔNQO2 and HCT1162ΔNQO2 responded to
the drug with a significant difference (IC50 values of 30.5 µM and 35.2 µM
respectively). HCT116NQO2+ had an IC50 value of 34.3 µM and was not significantly
different from either knockout cell line (Figure 16(e,f)).
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Figure 16: HCT116ΔNQO2 Cells Significantly More Sensitive to Kinase Inhibitor
Pacritinib. Crenolanib and Sunitinib Toxicity not Affected by NQO2 Status.
Kill curve of HCT116NQO2+ ( ), HCT1161ΔNQO2 (

), and HCT1162ΔNQO2 (

) cells after 18hr treatment

with varying concentrations of pacritinib (a), crenolanib (c), and sunitinib (e) respectively. Approximately
1,000 cells were initially seeded per well and each treatment condition has 5 wells (n=5). The % survival
was calculated by normalizing the absorbance of SRB dye to cells from each group treated with DMSO
vehicle control. Bar graph of calculated IC50 values for the respective conditions (b, d, f) with 95%
confidence intervals depicted as error bars. Data was plotted and analyzed in Prism 8.4.2, statistical
analysis performed was an ordinary one-way ANOVA with Tukey post-hoc test (* indicates P-value ≤
0.05, ** indicates P-value ≤ 0.01, *** indicates P-value ≤ 0.001, **** indicates P-value ≤ 0.0001, if
comparison not displayed relationship is ns) (GraphPad Software Inc).
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3.6
Crystal Structures of NQO2 and Sunitinib
Interaction
The crystal structures of NQO2 and most of the enzyme interacting drugs utilized in
this study have previously been determined (see reference 6 for NQO2-Chloroquine, 86
for NQO2-CK2 inhibitors, 92 for NQO2-Pacritinib/Crenolanib). Though identified as an
NQO2 binding drug by Klaeger et al. a structure of sunitinib and NQO2 binding had yet
to be determined. Characterizing the binding of NQO2 and interacting drugs is useful in
determining what properties make a drug well suited to NQO2 binding. Furthermore,
such studies have revealed different modes of binding depending on whether NQO2 is
oxidized or reduced with drugs having different affinities for each state of the enzyme
(6,74,86). Identifying the properties of NQO2-drug interactions may lead to a better
understanding of how NQO2 influences the mechanism of action of such drugs and is
therefore a worthwhile endeavor. For this thesis project, NQO2 was co-crystallized with
sunitinib and high resolution crystal structures of the NQO2-sunitinib interaction were
solved for the oxidized and reduced states of the protein.

3.6.1

Statistics for Data Collection
High resolution and quality data were collected from oxidized NQO2-sunitinib

crystals and reduced NQO2-sunitinib crystals. The statistics for the collections used to
refine structure are summarized in Table 3. Data for the oxidized NQO2 structure was
collected from “Crystal 3” and the data for the reduced NQO2 structure was collected
from “Crystal 1” (Table 1). Crystals were prepared in the specified conditions by
hanging drop.
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Table 3: Crystallographic Data Collection and Refinement Statistics.
Values in brackets are for the highest resolution shell.

3.6.2

Oxidized NQO2-Sunitinib Crystal Structure
Oxidized NQO2-sunitinib was refined using the structure for oxidized NQO2-

Chloroquine (PDB:4FGK with ligand removed from model) as a starting model. After
initial refinement run a structure was generated with an R-work/R-free of 0.1490/0.1833.
The generated model for NQO2 and FAD co-enzyme correlated very well with the
electron density. Substantial electron density was observed in both active sites of the
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enzyme above the isoalloxazine ring of FAD, as indicated by the Fo-Fc difference map
(Figure 17). That observation was consistent with previous structures depicting NQO2drug interactions and indicated that sunitinib was successfully co-crystalized with NQO2
and was bound to the active site.

Figure 17: Initial Refinement of OxNQO2-Sunitinib X-Ray Crystal Structure.
X-ray crystal structure of sunitinib in complex with oxidized NQO2 (green) in the active site over the
isoalloxazine ring of FAD (yellow), with Fo-Fc difference map contoured at 3 σ (green +, red -). Structure
solved to 1.47Å with an R-work of 0.1490 and R-free of 0.1833 using PDB:4FGK as a starting model. a,b)
Sunitinib density over the isoalloxazine of active site 1 of NQO2 shown from different perspectives. c,d)
Sunitinib density over the isoalloxazine of active site 2 of NQO2 shown from different perspectives. Data
collected at CLS, and refined using various software (MOSFLM, Scala, Phenix), structure rendered in
PyMOL.
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Sunitinib was placed into the observed electron density of the initial refined
structure using the Ligand Fit program and restraints for the drug (108). The correlation
coefficient (CC) for the fit of the ligand (sunitinib) was above the recommended score
(0.7) for an optimal fit in both active sites of NQO2. Active site 1 had a CC score of
0.787 and active site 2 had a CC score of 0.78. Subsequent refinement with the ligand in
the active site demonstrates that sunitinib sits above the isoalloxazine ring in each of the
active sites (Figure 18).

Figure 18: Sunitinib Binds the Active Site of OxNQO2.
X-ray crystal structure of sunitinib (magenta) in complex with oxidized NQO2 (green) in the active site
over the isoalloxazine ring of FAD (yellow), with 2Fo-Fc electron density contoured at 1 σ (blue). Structure
solved to 1.47Å R-work of 0.1839 and R-free of 0.2038. a,b) Sunitinib density over the isoalloxazine of
active site 1 of NQO2 shown from different perspectives. c,d) Sunitinib density over the isoalloxazine of
active site 2 of NQO2 shown from different perspectives. Data collected at CLS, and refined using various
software (MOSFLM, Scala, Phenix), structure rendered in PyMOL.
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Sunitinib binds with the active site through contacts with several residues and
water mediated interactions. The residues responsible for coordinating this interaction are
G149, N161, G174, A191, and I194. Four water molecules make contacts with sunitinib
and such residues. A polar interaction is maintained within sunitinib between an oxygen
and nitrogen that produces a conjugated ring system. These interactions are observed in
both active sites of the enzyme (Figure 19).

Figure 19: Interaction Between Sunitinib and NQO2 Coordinated by Water
Molecules and Residue Contacts in Active Site.
X-ray crystal structure of sunitinib (magenta) in complex with oxidized NQO2 (green) in the active site
over the isoalloxazine ring of FAD (yellow), with polar interactions shown with dashed lines. Structure
solved to 1.47Å R-work of 0.1839 and R-free of 0.2038. a,b) Sunitinib interactions with active site 1 of
NQO2 shown from different perspectives. c,d) Sunitinib interactions with active site 2 of NQO2 shown
from different perspectives. Data collected at CLS, and refined using various software (MOSFLM, Scala,
Phenix), structure rendered in PyMOL.
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The final refined structure of OxNQO2-Sunitinib was refined to 1.47Å and an Rwork/R-free of 0.1839/0.2038 (Figure 20(a)). Sunitinib interacts with each active site in
a similar manner. The interaction is coordinated by the same residue and water
interactions with slightly different orientations observed for the “tail” of the drug. The
planar structure of sunitinib allows the drug to enter the active site of NQO2 and align
itself over the isoalloxazine ring in each subunit (Figure 20(b,c)).

Figure 20: Sunitinib Sits Over the Isoalloxazine Ring of FAD in the Active Sites of
Oxidized NQO2
X-ray crystal structure of sunitinib (magenta) in complex with oxidized NQO2 (subunit A: green, subunit
B: cyan) in the active site over the isoalloxazine ring of FAD (yellow). Structure solved to 1.47Å, R-work
of 0.1839 and R-free of 0.2038. a) Sunitinib molecules bound in each active site of NQO2. Sunitinib and
FAD are shown in stick representations and NQO2 as a cartoon diagram. Sunitinib interactions with active
site 1 (b) and active site 2 (c) of NQO2. Protein is displayed as a surface representation. Data collected at
CLS, and refined using various software (MOSFLM, Scala, Phenix), structure rendered in PyMOL.

76

3.6.3

Reduced NQO2-Sunitinib Crystal Structure
Reduction of NQO2 co-crystallized with sunitinib was difficult to determine due

to the deep yellow colour of the drug. Previous reductions of NQO2 crystals were
monitored by the colour change of the crystal from yellow (when oxidized) to clear
(when reduced) (6,86). The deep colour of sunitinib meant that the colour of the crystal
would remain yellow regardless of how much reducing agent the crystal was soaked in.
Therefore, crystals were soaked several times with reducing soaks used previously to
achieve reduction and frozen in liquid nitrogen as quickly as possible (6).
Reduced NQO2-sunitinib was initially refined using the structure for reduced
NQO2-Ethidium bromide (PDB:4ZVK with ligand manually removed) used as a starting
model. After the first round of refinement, a structure was produced with 1.75Å
resolution and R-work/R-free values of 0.1844/0.2171. Significant electron density was
observed over the isoalloxazine ring of FAD in active site 1 (Figure 21(a,b)). Active site
2 had considerably less unaccounted for electron density over the isoalloxazine ring
(Figure 21(c,d)). Generally, the density for sunitinib was poorer in the reduced structure
than it was in the oxidized structure.
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Figure 21: Initial Refinement of RedNQO2-Sunitinib X-Ray Crystal Structure.
X-ray crystal structure of sunitinib in complex with reduced NQO2 (green) in the active site over the
isoalloxazine ring of FAD (yellow), with Fo-Fc difference map contoured at 3 σ (green +, red -). Structure
solved to 1.75Å with an R-work of 0.1844 and R-free of 0.2171 using PDB:4ZVK as a starting model. a,b)
Sunitinib density over the isoalloxazine of active site 1 of NQO2 shown from different perspectives. c,d)
Sunitinib density over the isoalloxazine of active site 2 of NQO2 shown from different perspectives. Data
collected at CLS, and refined using various software (MOSFLM, Scala, Phenix), structure rendered in
PyMOL.

Sunitinib was placed into the observed electron density of the initial refined
structure using the Ligand Fit program and restraints for the drug (108). The correlation
coefficient (CC) for the fit of the ligand (sunitinib) was below the recommended score
(0.7) for an optimal fit in both active sites of NQO2. Active site 1 had a CC score of 0.62
and active site 2 had a CC score of 0.586. Subsequent refinement with the ligand in the
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active site demonstrates that sunitinib sits above the isoalloxazine ring in each of the
active sites though considerable density is missing for a portion of the drug. Sunitinib
also takes on two different conformation between the active sites. The fit for sunitinib in
active site 1 places the drug further in the active site (Figure 22(a,b)). Active site 2 had a
poorer score for the fit for sunitinib, the drug is observed to bind more shallowly and is in
a twisted conformation (Figure 22(c,d)).

Figure 22: Sunitinib Binds the Active Site of RedNQO2.
X-ray crystal structure of sunitinib (magenta) in complex with reduced NQO2 (green) in the active site over
the isoalloxazine ring of FAD (yellow), with 2Fo-Fc electron density contoured at 1 σ (blue). Structure
solved to 1.75Å R-work of 0.1794 and R-free of 0.2190. a,b) Sunitinib density over the isoalloxazine of
active site 1 of NQO2 shown from different perspectives. c,d) Sunitinib density over the isoalloxazine of
active site 2 of NQO2 shown from different perspectives. Data collected at CLS, and refined using various
software (MOSFLM, Scala, Phenix), structure rendered in PyMOL.
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Examining the polar interactions in the active sites of reduced NQO2 reveals
distinct differences in sunitinib’s mode of binding when compared to the oxidized
enzyme. In active site 1 sunitinib interacts with three water molecules and the G174 and
N161 residues. Interactions with G149, A191 and I194 are not observed and there is 1
fewer water molecule than the oxidized structures (Figure 23(a,b)). The polar interaction
between an oxygen and nitrogen of sunitinib is broken for the fit of the drug in active site
2, putting the drug in a twisted and non-favored conformation. The drug interacts with
four water molecules and the G149, N161, and G174 residues (Figure 23(c,d)).

Figure 23: Interaction Between Sunitinib and Reduced NQO2 Distinct from Binding
Observed in Oxidized Structure.
X-ray crystal structure of sunitinib (magenta) in complex with reduced NQO2 (green) in the active site over
the isoalloxazine ring of FAD (yellow), with polar interactions shown with dashed lines. Structure solved to
1.75Å R-work of 0.1794 and R-free of 0.2190. a,b) Sunitinib interactions with active site 1 of NQO2
shown from different perspectives. c,d) Sunitinib interactions with active site 2 of NQO2 shown from
different perspectives. Data collected at CLS, and refined using various software (MOSFLM, Scala,
Phenix), structure rendered in PyMOL.
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Reduced NQO2 bound to sunitinib was refined to a final resolution of 1.75Å with
an R-work of 0.1794 and R-free of 0.2190 (Figure 24(a)). Sunitinib was found to bind
differently to each active site. The drug sits deeper in active site 1 and polar bonds within
the drug are maintained, leading to a more planar conformation (Figure 24(b)). Though
sunitinib makes more contacts with the protein in active site 2, the electron density
suggests an un-favorable conformation for the drug (Figure 24(c)).

Figure 24: Sunitinib Sits Over the Isoalloxazine Ring of FAD in the Active Sites of
Reduced NQO2
X-ray crystal structure of sunitinib (magenta) in complex with reduced NQO2 (subunit A: green, subunit B:
cyan) in the active site over the isoalloxazine ring of FAD (yellow). Structure solved to 1.75Å, R-work of
0.1794 and R-free of 0.2190. a) Sunitinib molecules bound in each active site of NQO2. Sunitinib and FAD
are shown in stick representations and NQO2 as a cartoon diagram. Sunitinib interactions with active site 1
(b) and active site 2 (c) of NQO2. Protein is displayed as a surface representation. Data collected at CLS,
and refined using various software (MOSFLM, Scala, Phenix), structure rendered in PyMOL.
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3.7
Label-Free Mass Spectrometry for Proteome
Characterization of HCT116NQO2+ and HCT116ΔNQO2 Cell
Lines
Proteins from HCT116 cell samples were identified and relative abundance
determined with Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS).
Label-free mass spectrometry was chosen as a technique for its broad application and
relative ease compared to other mass spectrometry approaches. Five samples from each
of HCT116NQO2+, HCT1161ΔNQO2, and HCT1162ΔNQO2 were analyzed at the Don Rix
Protein Identification Facility (University of Western Ontario). Upon analysis of the data
it was determined that the proteome of HCT116NQO2+ cells was significantly different
from the HCT116ΔNQO2 cell lines. The results indicate that the abundance of a variety of
proteins is influenced by NQO2 and reveals potential regulatory roles for NQO2. This
experiment was conducted to investigate a potential role for NQO2 as a flavin-redox
switch and to identify differences in the proteomes of NQO2 knockout cells that may
explain their differing response to drug treatments.

3.7.1

Analysis of Mass Spectrometry Data by Cell Line
The raw files from mass spectrometry experiments were initially processed in

MaxQuant to match peptide sequences to protein sequences and generate a list of
identified proteins with relative abundance values for each sample. After this was
completed bioinformatics was performed in Perseus. For the HCT116NQO2+ samples, an
average of 4592 proteins were identified. An average of 4643 and 4645 were identified
and assigned label free quantification (LFQ) values for the HCT116ΔNQO2 cell lines
(1ΔNQO2 and 2ΔNQO2 respectively) (Figure 25(a)). A numeric venn diagram was
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generated to see the overlap in identified proteins between the groups. There were 4677
proteins that were identified at least once in each of the cell lines. HCT116NQO2+ samples
had 16 proteins identified that did not appear in the results for the knockout cell lines,
NQO2 being among them. The knockout cell lines had 22 proteins that were identified
from their samples but not in the NQO2 expressing cell line (Figure 25(b)). The gene
names for the proteins exclusive to either HCT116NQO2+ or the HCT116ΔNQO2 cell lines
are listed in Figure 25(c).
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Figure 25: Label-Free Mass Spectrometry of HCT116NQO2+, HCT1161ΔNQO2, and
HCT1162ΔNQO2 Cells.
a) Average of the total number of proteins identified and assigned an LFQ value for each cell line. b)
Numeric Venn Diagram of proteins identified in each group at least once across 5 replicates (n=5). c) List
of the gene names of the proteins from the numeric Venn Diagram that were identified exclusively in the
HCT116NQO2+ cell line or exclusively in both the HCT116ΔNQO2 cell lines. Bioinformatics was performed in
Perseus.
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A principle component analysis performed on the dataset revealed that the
samples for the HCT116NQO2+ cells separated out from the HCT116ΔNQO2 cell lines along
the first principal component. This indicates the majority of the variation in the dataset
can be attributed to whether or not NQO2 is expressed in the cells. The NQO2 knockout
cell lines group together and suggests similarity in their datasets (Figure 26). The
principle component analysis suggests that NQO2 knockout cells have proteomes that are
similar to each other but distinct from the cells that express NQO2.

Figure 26: HCT116ΔNQO2 Samples Group Together and Separate from HCT116NQO2+
Cells Indicating Distinct Proteomic Profiles.
Principal component analysis of raw LFQ data for each replicate of HCT116 cell samples analyzed by label
free mass spectrometry. 5 replicates from each cell line (n=5) were analyzed. HCT116 NQO2+ displayed in
red, HCT1161ΔNQO2 shown in green and HCT1162ΔNQO2 in blue.
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After preliminary analysis the datasets were grouped by cell line, filtered to only
include proteins that were quantified 70% of the time in one of the groups, then missing
values filled in from a normal distribution. The LFQ values were also log2 transformed to
allow for easier examination of quantification values. Each group of cell lines was
subjected to statistical tests in the form of t-tests between each other to compare whether
the mean LFQ values for identified proteins were different. For proteins to be considered
as significantly different at least a 2-fold change in abundance had to be observed
between the groups with a p-value ≤ 0.05. When comparing HCT116NQO2+ to
HCT1161ΔNQO2, 83 proteins were shown to have 2-fold higher LFQ values in
HCT116NQO2+ and 90 proteins had at least 2-fold lower LFQ values (Figure 27(a)).
Similarly, 79 proteins had significantly higher abundance in HCT116NQO2+ cells when
compared to HCT1162ΔNQO2 cells, with 83 proteins having significantly lower abundance
in the NQO2 expressing cell line (Figure 27(b)). The changes in the proteomes between
the NQO2 knockout cell lines were far less drastic. Comparing HCT1161ΔNQO2 to
HCT1162ΔNQO2, just 3 proteins had significantly higher LFQ values and 8 were found to
have lower LFQ values (Figure 27(c)). The volcano plots demonstrate that knocking out
NQO2 in HCT116 cells leads to extensive changes in the proteomes of the cells. The
similarity of the proteomes for the HCT116ΔNQO2 cells shows that the changes to the
proteome caused by the knockout of NQO2 are not random.
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Figure 27: Pronounced Statistically Significant Differences Observed Between the
Proteomes of HCT116NQO2+ Cells and HCT116ΔNQO2 Cells.
Volcano plots of a) HCT116NQO2+ vs. HCT1161ΔNQO2 b) HCT116NQO2+ vs. HCT1162ΔNQO2 c) HCT1161ΔNQO2
vs. HCT1162ΔNQO2. Students T-test difference (Log2) plotted against –Log students T-test p-value for each
identified protein for the respective groups being compared. Green points represent proteins with p-values
< 0.01, blues points represent proteins with 0.01 < p-values < 0.05, dashed lines represent 2-fold LFQ
differences and a p-value= 0.05.

3.7.2

Functional Enrichment Analysis of Proteins with Significant
Changes Between HCT116NQO2+ and HCT116ΔNQO2 Cells
The list of gene names for proteins that had higher or lower abundance in

HCT116NQO2+ compared to the respective knockout cell line were taken and used for
enrichment analysis. Before conducting the enrichment analysis the proteins with a
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significant change that were in common between the HCT116NQO2+ vs HCT1161ΔNQO2 and
the HCT116NQO2+ vs HCT1162ΔNQO2 comparisons were determined. To that end Venn
diagrams were generated to assess the overlap in the lists of gene names for proteins with
significant differences. For the proteins that had significantly higher LFQ values in
HCT116NQO2+, relative to the knockouts, 53 proteins were common between the lists with
30 being exclusive to the HCT1161ΔNQO2 comparison and 26 to the comparison with the
second knockout cell line (Figure 28(a)). When examining the proteins with lower LFQ
values there were 51 proteins that had decreased abundance in HCT116NQO2+ when
compared to each of the knockouts. Thirty nine proteins were significantly lower in
abundance only when compared to the first knockout cell line and 32 proteins for the
comparison of HCT116NQO2+ to HCT1162ΔNQO2 (Figure 28(b)). A total of 104 proteins
had significant changes in their relative abundance in the HCT116NQO2+ cell line when
compared to both of the NQO2 knockout cell lines, 53 of which were greater in
abundance in the NQO2 expressing line and 51 that had decreased abundance (See
Supplementary Tables 1 and 2).
Using the lists of proteins with either greater or lower LFQ values an enrichment
analysis for cellular component was performed with all human proteins as the
background in FunRich. The analysis for proteins with greater abundance revealed that
the group was significantly enriched with exosome associate proteins. 41.3% of the
proteins in the list have an association to exosome function, an enrichment highly
unlikely to occur by chance. (Figure 28(c)). Lysosome associated proteins were enriched
to 40% in the group of proteins with lower LFQ values in HCT116NQO2+, a statistically
significant result (Figure 28(d)).
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Figure 28: Enrichment Analysis in FunRich Reveals Significant Enrichment of
Exosome and Lysosome Associated Proteins in Mass Spectrometry Dataset.
Venn diagram of proteins with greater (a) or lower (b) abundance in HCT116NQO2+ relative to
HCT1161ΔNQO2 (blue) vs HCT116NQO2+ relative to HCT1162ΔNQO2 (red). c) Enrichment analysis for cellular
component using 53 proteins that had higher LFQ values in HCT116NQO2+ relative to HCT116ΔNQO2 cell
lines. d) Enrichment analysis for cellular component using 51 proteins that had lower LFQ values in
HCT116NQO2+ relative to HCT116ΔNQO2 cell lines. Blue bars represent percentage of genes in the data set
with an association with respective cellular component. Red line represents significance cutoff (p-value =
0.05), and yellow points display calculated p-value for the enrichment.
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A further analysis was performed using a combination of g:Profiler and
Cytoscape. The background for functional enrichment analysis can be customized in
g:Profiler to consider only the scope of the experimental technique used. For the
enrichment analysis of proteins with significant changes in the mass spectrometry dataset
the background was limited only to the gene names of all the proteins identified by labelfree mass spectrometry. Adjusting the background provided for a more accurate statistical
landscape to consider only those proteins that were possible to have been detected.
The groups of proteins that were significantly higher in HCT116NQO2+ and those
that were significantly lower in abundance were analyzed independently at first and the
results of functional enrichment analysis displayed in Cytoscape. When looking at the
enrichment of the gene lists for cellular component many significant enrichments were
observed. The data were grouped into clusters and annotated with word clouds to convey
the commonalities of the clusters (Figure 29(a)). For the proteins that were more
abundant in HCT116NQO2+ (relative to the NQO2 knockout cell lines) 5 clusters for the
significantly enriched cellular components were formed; Membrane region raft, Cell
substrate junction, Extracellular space region, Contractile fiber myofibril, and Actin
cytoskeleton. The list of proteins that were significantly lower in abundance were
significantly enriched for proteins associated with two cellular components namely;
Anchored component of external side of plasma membrane, and Anchored component of
membrane. The summary of the functional enrichment analysis for cellular component is
displayed in Table 4.
When assessing the enrichment for molecular function two significant results
were observed in the group of proteins with greater LFQ values in the NQO2 expressing
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cell line. The group with greater abundance was significantly enriched with proteins
associated with actin binding and S100 protein binding (Figure 29(b)). Three biological
pathways were also found to be significantly enriched in the list of proteins that were less
abundant in the HCT116NQO2+ cell line when compared to the HCT116ΔNQO2 cell lines.
The proteins disproportionately have functions in hematopoietic stem cell differentiation,
human complement system, and differentiation pathways (Figure 29(c)).

Figure 29: Enrichment Analysis of Proteomic Changes Between HCT116NQO2+ and
HCT116ΔNQO2 Cells Identifies Cellular Functions Regulated by NQO2.
The significant differences in the proteomes of the HCT116 cell line were processed in g:Profiler and
reports for functional enrichment analyses generated. Functional enrichment analysis results were
examined in Cytoscape. Cellular component analysis (a) for proteins with greater LFQ values ( ) or lower
LFQ values ( ) in HCT116NQO2+ cells. Functions were clustered for similarity and word clouds generated
for grouped cellular components. Molecular function enrichment analysis (b) for proteins with greater
abundance ( ) in HCT116NQO2+ cells. Biological pathways enrichment analysis (c) for proteins with
decreased abundance ( ) in HCT116NQO2+ cells.
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Table 4: Summary of Clustering for Functional Enrichment Analysis of Cellular
Component for Significant Label-Free Mass Spectrometry Changes.

The proteins with significant differences were also analyzed as a whole,
regardless of whether their LFQ values were higher or lower between the groups. A total
of 17 cellular components were over-represented in the dataset and could be grouped into
3 distinct clusters. The autogenerated annotations for the clusters were Extracellular
vesicle space, External side membrane, and Membrane microdomain raft (Figure 30(a)).
To summarize the functional enrichment analysis the totality of the proteins with
significant changes in abundance were disproportionately associated with cellular
components of the cell membrane or extracellular space/vesicles (Figure 30(b)).
Functional enrichment analysis using the combination of g:Profiler and Cytoscape
allowed for more precise and robust results than FunRich though the results correlate
rather well since exosomes appeared in both methods as well as cellular components
associated with lysosome function. A great number of possible roles for NQO2 have been
identified through functional enrichment analysis of the mass spectrometry data and can
inform future study design.
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Figure 30: Functional Enrichment Analysis of all Proteins with Significant Changes
in Mass Spectrometry Experiment of HCT116 Cells.
The significant differences in the proteomes of the HCT116 cell line were processed in g:Profiler and
reports for functional enrichment analyses generated. Functional enrichment analysis results were
examined in Cytoscape. Cellular component analysis (a) for proteins with significantly different LFQ
values between the HCT116NQO2+ and HCT116ΔNQO2 groups. Functions were clustered for similarity and
word clouds generated for grouped cellular components. b) Summary of clustering and word cloud
annotations.
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3.7.3

Exosome Isolation from HCT116 Cell Lines
The functional enrichment analysis revealed that proteins associated with

exosomes (and extracellular vesicles generally) were significantly enriched in the set of
proteins with significant differences in the mass spectrometry dataset. Exosomes were
isolated from the HCT116 cell lines to see if they could successfully be collected. Being
able to collect exosomes from these cell lines would allow for the design of experiments
to test the relationship between NQO2 and exosome function/composition.
Briefly, exosomes were collected by culturing 80% confluent cell cultures in
serum free media for 48hrs. The media was collected and several rounds of centrifugation
performed to remove detached cells and debris. Extracellular vesicles were pelleted by
ultracentrifugation and resuspended in PBS. Exosome samples were resolved by SDSPAGE (Figure 31(a)) and transferred to a PVDF membrane for western blotting. The
exosome specific marker CD9 was used to detect the presence of exosomes in the
collected samples and GAPDH was used as a loading control as a common cargo for
extracellular vesicles.
The second exosome preparation yielded far greater amounts of extracellular
vesicles. For the first preparation of exosomes neither CD9 nor GAPDH could be
detected by western blot in any of the cell lines. GAPDH was detectable in all cell lines
for the second preparation. HCT116NQO2+ had the highest levels of CD9 in the exosome
preparation and HCT1161ΔNQO2 had much lower levels of the exosome marker. CD9 was
not detected in the preparation from HCT1162ΔNQO2 cells (Figure 31(b)).
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Figure 31: Exosome isolation from HCT116 cell lines.
a) 12% SDS-PAGE of exosome isolations from HCT116NQO2+, HCT1161ΔNQO2, and HCT1162ΔNQO2 cells.
Two separate preparations of exosomes were prepared for each cell line. b) Western blot of both exosome
preparations from HCT116NQO2+, HCT1161ΔNQO2, and HCT1162ΔNQO2 cells respectively. Membranes were
probed for GAPDH and CD9 with specific antibodies. GAPDH as a known cargo of exosome vesicles and
CD9 as an exosome specific marker.

3.7.4

Validation of Mass Spectrometry Results for CD73
The CD73 protein had one of the largest changes in average LFQ values between

the HCT116NQO2+ cells and the HCT116ΔNQO2 cells. The protein was 16.4 times higher in
HCT1161ΔNQO2 cells and 25.5 times higher in HCT1162ΔNQO2 cells relative to
HCT116NQO2+. CD73 is a member of the NTPDase family and catalyzes the breakdown
of AMP into adenosine and free phosphate in the extracellular space (119).
Expression levels of the protein in the HCT116 cell lines was assessed by western
blot to determine if the mass spectrometry results could be confirmed through an
alternative method. Plates of the respective cell lines were grown to 80% confluency
before being collected, lysed and samples prepared for the experiment. GAPDH was used
as a loading control and for normalization of CD73 levels. CD73 was barely detectable in
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HCT116NQO2+ cells but had much higher expression in the HCT116ΔNQO2 cell lines
(Figure 32(a)). The levels of CD73 in HCT1161ΔNQO2 cells was about 6.2 times higher
than in the NQO2 expressing cell line and levels of the ecto-nucleotidase were about 9.6
times higher in HCT1162ΔNQO2 cells (Figure 32(b)).

Figure 32: CD73 Expression Greater in Both HCT116ΔNQO2 Cell Lines.
Western blot (a) of HCT116 cell lines from 80% confluent plates. Lysates of cell lines were resolved by
SDS-PAGE and transferred to a PVDF membrane. Specific antibodies for CD73 and GAPDH were used as
primary antibodies and fluorescent Licor antibodies used for detection. Densitometric analysis (b) of CD73
levels normalized to GAPDH for the respective cell lines. Densitometric analysis performed in Image
Studio lite.
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Chapter 4 – Discussion

4

Findings Summary
The results of this study advance the understanding of the role of NQO2 in

regulation and drug interactions. Observations from this thesis support the hypothesis that
NQO2 can function as a flavin-redox switch but also reveals novel cellular functions that
NQO2 may influence. Several experimental approaches were utilized to investigate the
function of NQO2. A cellular biology approach was used to investigate NQO2 dependent
effects of treating cells with NQO2 interacting drugs (for chemical structures of drugs
and summary of targets see Supplementary Figure 1 and Supplementary Table 3).
Structural analyses of NQO2 interactions with the clinical kinase inhibitor sunitinib were
also conducted through use of x-ray crystallography. Finally, a proteomics approach was
done to identify how NQO2 expression alters the proteome and to identify possible
regulatory roles for NQO2. Mass spectrometry revealed that cells that express NQO2
have distinct proteomes from cells with the gene for the enzyme knocked out and can be
used to inform research into functions of the protein beyond quinone catalysis. This thesis
is impactful in the field because it has identified NQO2 dependent effects resulting from
the treatment of several drugs. It has also identified proteins and cellular functions that
have an association with NQO2 expression, information that can be utilized to explain the
peculiar effects and characteristics of NQO2.

4.1 HeLaΔNQO2 Cell Characterization
The HeLa cell lines used in this study were previously generated by Brian Shilton
(unpublished work) and the knockout of the NQO2 gene confirmed. HCT116 cells with
NQO2 knocked out were also previously generated by Kevin Leung (101). In addition to
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gene knockout and abrogation of NQO2 protein expression the proliferation and ability of
the cells to reduce CB1954 was also characterized.
The HCT116ΔNQO2 cells were shown to proliferate at slightly slower rates than the
cell line that expresses NQO2 (101). This effect appears to be most pronounced after
cells are seeded into a new plate and anecdotally would seem to be due to slower cell
attachment to the plate surface, though a way to quantify such an observation would be
needed. A similar phenomenon was observed for the HeLa cell lines used in this study
which also had slower initial proliferation rates with large gaps in absorbance of SRB dye
at days 3 and 4 (Figure 3). Knocking down NQO2 in other cancer cell lines was also
reported to slow the proliferation of cells, an observation linked to interactions between
NQO2 and CCAAT-enhancer-binding protein α (C/EBPα) (120). Multiple observations
of slowed cell growth when NQO2 is either knocked out or down indicates the result is
not coincidental. This phenomenon however requires further investigation to determine
why this occurs and to identify how NQO2 regulates cell growth.
To demonstrate that NQO2 enzymatic activity does not occur in the NQO2
knockout cell lines the cytotoxicity of NQO2 specific substrate CB1954 was assessed.
When HeLa cells that express NQO2 are subjected to CB1954 treatment, activation of the
drug is only observed when NRH is added to the culture conditions (Figure 4(a)). The
addition of NRH to media allows NQO2 to perform its latent enzymatic function and thus
reduce CB1954 into a cytotoxic compound. The activation of this drug leads to a nearly
100-fold change in the IC50 value signifying much more severe cell toxicity (Figure
4(b)). Performing the same experiment on the HeLaΔNQO2 cell line shows no difference
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between the conditions when NRH was supplemented or wasn’t (Figure 4(a)). That
result indicates that CB1954 is not becoming activated in the NQO2 knockout cell line.
The same experiments were also performed in the HCT116 cell lines and yielded the
same observations (101). The CB1954 toxicity assays are important as they prove several
points in one experiment. Firstly, they verify that NQO2 activity has been abolished in
the knockout cell lines and that the CB1954 substrate is specific to NQO2. Secondly it
demonstrates that there are not usable co-substrates for NQO2 present in the cells or in
the standard culturing media for the respective cell lines. The experiments provide further
confidence in the use of NQO2 knockout cells and proves that it is unlikely that NQO2
will have enzymatic function in cellular studies where NRH is not supplemented into
culture conditions.

4.2
Toxicity of NQO2 Interacting Drugs in Cells and
Dependency on NQO2 Expression
Previous experiments on the HCT116 cell lines failed to identify any significant
differences in how the cell lines that express NQO2 versus those that do not, respond to
treatment with drugs that have been shown to bind to NQO2 (101). The previously
assayed drugs with no difference between the cell lines were TBB, TBBz, DMAT,
Ethidium Bromide, Acridine Orange, and Doxorubicin. This study expanded the scope of
study to encompass an additional cell line (HeLa cells) and additional drugs, namely
several clinical kinase inhibitors and the antimalarial drug chloroquine. The use of
chloroquine in combination with other NQO2 interactors was also examined. Results
from this study indicate that there is an NQO2 dependency on the toxicity of some of the
assayed drugs but also cell line specific effects.
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For instance, HeLaΔNQO2 cells were far more sensitive to TBBz and DMAT than
the NQO2 expressing counterparts, while there is no dependency on NQO2 expression in
the HCT116 cell lines (Figures 5, 8, 9, 10). The opposite effect was seen in the HeLa cell
lines when treated with sunitinib and survival determined by SRB assay. In that
experiment the HeLa cells that express NQO2 were more sensitive to the drug than the
cell line that does not express the protein (Figure 15(e,f)). When the HCT116 cells were
treated with pacritinib, both the HCT116ΔNQO2 cell lines were found to be about twice as
sensitive to the drug when compared to the HCT116NQO2+ cells, indicating NQO2
provides some protective effect (Figure 16(a,b)). On the other hand, the HCT116 cells
that express NQO2 are significantly more sensitive to the autophagy inhibitor,
chloroquine (Figures 13(c,d), 14(c,d)). There were also NQO2 dependent effects
resulting from chloroquine co-treatment with other NQO2 interacting drugs.
In the case of the HeLaΔNQO2 cells and their increased sensitivity to TBBz and
DMAT, the effect appears to be due to increased apoptosis as determined from the PARP
cleavage assay (Figure 6). This apoptosis may not be occurring in the HCT116 cells and
may explain why NQO2 knockout cells have similar susceptibilities to TBBz and DMAT
while HeLa cells do not. A more comprehensive analysis of how NQO2 contributes to
the effects of such drugs is warranted but the results of this project indicate that some of
the mechanisms are dependent upon NQO2 in certain contexts.
The HeLa and HCT116 cancer cell lines both express wild-type p53 though the
HPV infection present in HeLa cells contributes towards a high turnover rate of the tumor
suppressor (121,122). Such a difference between the cell lines may be contributing to the
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varied effects of the drugs and merits further investigation. Given the marked differences
between various cell lines it is expected to observe differences in both response to drugs
and NQO2’s role in the response. Further research would benefit from establishing
NQO2 knockout cells in a variety of other cell lines and performing similar experiments.
The results of the drug treatments performed in this project will be summarized in the
following sections.

4.2.1

NQO2 Dependent Effects of CK2 Inhibitor Drugs
The CK2 inhibitor drugs TBB, TBBz, and DMAT were tested for toxicity in the

cell lines used for this study. It was previously found that TBBz and DMAT were potent
apoptosis inducers independent of their interactions with CK2 (78). When NQO2 was
identified as a high affinity binder to these drugs, and not TBB, it was speculated that
NQO2 was contributing to the apoptotic effects of the drugs. The toxicity assays
performed on the HeLa and HeLaΔNQO2 cell lines indicate that NQO2 is providing a
protective effect to the cells when treated with TBBz or DMAT rather than promoting
apoptosis (Figure 5(c-f)). That observation is consistent with the observations from the
western blots for cleaved PARP, wherein less of the PARP protein was getting cleaved in
the HeLa cells when treated with the respective drugs (Figure 6). No significant
difference between cell line response to treatment with TBB was observed in the HeLa
cells (Figure 5(a,b)). This was expected as NQO2 is a very weak interactor with this
drug and likely has no contribution to the effects of the drug.
Western blots for PARP cleavage were also conducted for 18hr, 24hr and 48hr
timepoints, though there was difficulty in detecting the loading control (GAPDH) in
those samples but PARP appeared much more clearly (Supplementary Figure 2(a)). The
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results from those experiments indicate that at the 18hr timepoint TBBz and DMAT
induce apoptosis to a greater degree in the HeLaΔNQO2 cell line (Supplementary Figure
2(b)). The ratio of cleaved PARP:PARP increases for TBBz and DMAT at the 24hr
treatment times for both cell lines and doses administered. At that time point the
induction of apoptosis is relatively equal for the drugs between the HeLa and HeLaΔNQO2
cell lines (Supplementary Figure 2(c)). When treated for 48hrs the ratio of cleaved
PARP:PARP becomes higher in the HeLa cells than observed in the HeLaΔNQO2 cells
(Supplementary Figure 2(d)), though this may be attributable to nearly all the cells in
the HeLaΔNQO2 plates exposed to TBBz or DMAT for that length of time being dead as
evident by the amount of floating debris in the samples. TBB is a relatively weak inducer
of PARP cleavage in both cell lines, appreciable cleavage of PARP was not detected until
TBB was administered for 48hrs. Irrespective of NQO2’s contribution to apoptosis when
treated with such drugs, the CK2 inhibitors that bind to NQO2 (TBBz and DMAT) are
much more potent drugs.
Experiments using chloroquine in combination with the CK2 inhibitors were also
conducted to see if the effects could be enhanced with low doses of the autophagy
inhibitor. The HeLa and HeLaΔNQO2 cells responded to TBB treatment no differently
between the 0 µM or 20 µM chloroquine treatment conditions and there was also no
significant difference between the cell lines (Figure 7(a,b)). HeLaΔNQO2 cells were found
to be significantly more sensitive to TBBz than the HeLa cells in the 0 µM chloroquine
condition, aligning with the previous experiment. When chloroquine was administered
HeLa cell sensitivity to treatment was significantly increased while no significant
changes in the IC50 values of the HeLaΔNQO2 cells were seen (Figure 7(c,d)). HeLa cells
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are significantly more sensitive to TBBz when also treated with 20 µM chloroquine,
compared to the NQO2 knockout cells which would indicate that NQO2 plays a role in
enhancing the toxicity of TBBz when exposed to chloroquine. The toxicity of DMAT
was about equal between the HeLa and HeLaΔNQO2 cell lines in both the 0 µM and 20 µM
chloroquine conditions and each cell line saw a significant decrease in the IC50 value of
the drug when chloroquine was applied to cells (Figure 7(e,f)). In this instance an NQO2
dependent effect was not observed and chloroquine sensitized both cell lines. It is of note
that the IC50 values of all treatments are much lower for the drugs than what was
observed in Figure 5. The only differences between the experiments was that this one
seeded cells at twice the initial density for concern that combining the drugs would kill
too many cells too early to have any detectable signal at the end of the experiment, the
cells in the 0 µM chloroquine conditions were also treated with PBS as a vehicle control
for the 20 µM chloroquine condition. It is unclear why this would cause such a
discrepancy in the IC50 values for each drug but, it is important to note that this occurred.
Toxicity assays of the CK2 inhibitors on the HCT116NQO2+, HCT1161ΔNQO2, and
HCT1162ΔNQO2 previously showed no differences in cell response to treatment between
the cell lines (101). In this study the experiment was repeated but with the use of
chloroquine in combination treatment with the drugs to see if an NQO2 dependent
phenotype would become apparent when NQO2 interacting drugs were combined. When
cells were treated with the respective drugs and 0 µM chloroquine no difference in
sensitivity between the cell lines were observed (Figures 8-10). The results for this
experiment were consistent with the observations made by Kevin Leung in his thesis in a
similar experiment (101). Whereas HeLa cells with NQO2 knocked out are more
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sensitive to TBBz and DMAT, NQO2 status in HCT116 cells consistently has no effect
on CK2 inhibitor toxicity. The addition of 10 µM chloroquine to the treatment conditions
had a slight sensitizing effect for each drug though the IC50 values were not significantly
different between chloroquine dose groups or between HCT116 cell lines (Figures 8-10).
The error bars in the 0 µM treatment conditions were quite large and merits further
investigation with larger sample sizes.

4.2.2

Clinical Kinase Inhibitor Drugs and NQO2 Relationship to
Cell Toxicity
NQO2 is frequently identified as an off-target interactor with kinase inhibitors

and it has been much speculated that the interactions may be influencing the effects of
such drugs (87, 89, 90). Imatinib for instance is a clinical drug that binds to NQO2,
despite its extensive clinical use not much headway has been made on the topic of NQO2
dependent or mediated effects of the drug. The comprehensive paper on clinical kinase
inhibitor binding profiles published by Klaeger et al. demonstrated that NQO2 is an even
more pervasive off-target binder with kinase inhibitors than thought (92). Such a
discovery necessitates understanding NQO2’s interactions with such drugs for a variety
of reasons. For instance, NQO2 mediated effects with the drugs could be exploited to
increase the efficacy of the compounds. Imatinib has long been the first line treatment for
CML but the development of Imatinib resistance in some cases has necessitated
modifications of treatment regimens or the use of other kinase inhibitors such as sunitinib
(93,123,124). A better understanding of NQO2 interactions with the drug would inform
such endeavors and may lead to more effective treatments.

104

SRB assays for cell survival were conducted on HeLa and HeLaΔNQO2 cells after
treatment with either pacritinib, crenolanib, or sunitinib (all high affinity interactors with
NQO2). After 48hr treatments there was no difference found between the HeLa and
HeLaΔNQO2 cells when treated with either pacritinib or crenolanib (Figure 15(a-d)). The
calculated IC50 values for sunitinib treatment however were significantly different
between the two cell lines. HeLa cells that express NQO2 were found to be more
sensitive to the drug and indicates a mild contribution of NQO2 towards the killing action
of the drug (Figure 15(e,f)).
An SRB assay experiment conducted with the same drugs over 18hr treatment
times yielded different results in the HCT116 cell lines. HCT116NQO2+ cells were found
to be significantly less sensitive to pacritinib than both the HCT116ΔNQO2 cell lines were,
with about a 2-fold difference in the calculated IC50 values (Figure 16(a,b)). Crenolanib
was equally toxic to all HCT116 cell lines, with NQO2 status in the cells having no
impact, as was seen in the HeLa cells (Figure 16(c,d)). The only significant difference in
the HCT116 cells when treated with sunitinib for 18hrs occurred between the two
HCT116 NQO2 knockout cell lines, suggesting that NQO2 has no impact on the toxicity
of sunitinib in HCT116 cells (Figure 16(e,f)). These experiments reveal the toxicity of
sunitinib and pacritinib can be influenced by the expression of NQO2 but, the effect is
only seen in specific cell lines.
The results of previous studies looking at the combination of sunitinib and
chloroquine treatment was used to inform experiments for this project. Combined use of
chloroquine and sunitinib has been shown to act synergistically to decrease tumor volume
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in mouse cancer models and to inhibit proliferation of various cancer cell lines (98,99).
These studies did not examine the role NQO2 plays in the synergism of the drugs, given
that both the drugs interact with NQO2 it seemed as though the protein was likely
involved in the mechanism. The NQO2 knockout cell lines we have were utilized to
compare the responses of combined use of these drugs between cells that do and do not
express the enzyme.
MTT assays performed on HeLa cells and HeLaΔNQO2 cells to test the ability of
chloroquine to sensitize cells to sunitinib were conducted and found no significant
differences between the cell lines or between chloroquine dose groups (Figure 11). It
could be concluded that at the doses of chloroquine used in the experiment (up to 5 µM)
sunitinib sensitivity did not change and NQO2 played no role in cell response to
treatment.
A comparable experiment in the HCT116 cell lines examined sunitinib dose
curves in combination with doses up to 10 µM chloroquine. This experiment found
difference between the cell lines in response to treatment as well as differences between
the chloroquine dose groups (Figure 12(a-c)). HCT1161ΔNQO2 was most sensitive to
sunitinib treatment in the 0 µM chloroquine dose group, having an IC50 value
significantly different from HCT116NQO2+ but not the other knockout cell line.
HCT116NQO2+ and HCT1162ΔNQO2 had comparable IC50 values meaning the difference
observed with the first knockout cell line was likely not due to NQO2 (Figure 12(d)).
When treated with a range of doses of sunitinib and a constant concentration of 2 µM
chloroquine the calculated IC50 values for each cell line were indistinguishable
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statistically, having a value of about 2 µM. HCT116NQO2+ cells were the least sensitive to
sunitinib when co-treated with 10 µM chloroquine and had an IC50 for those treatment
conditions that was statistically difference from both the NQO2 knockout cell lines
(Figure 12(d)). When looking at how each cell line responded to sunitinib with different
doses of chloroquine sensitization to sunitinib was observed for each cell line.
HCT116NQO2+ cells were sensitized to sunitinib when 2 µM chloroquine was
administered and no difference was observed when 10 µM chloroquine was applied to
cells treated with sunitinib (Figure 12(e)). Sensitization of the HCT1161ΔNQO2 cells only
occurred when 10 µM chloroquine was given with the kinase inhibitor while
HCT1162ΔNQO2 cells become more sensitive with each change in chloroquine
concentration (Figure 12(e)). The results are somewhat mixed regarding NQO2’s
contribution to the effects of these two drugs but, does show that greatest toxicity
occurred in the NQO2 knockout cells when the drugs were combined.
Since the combination of sunitinib and chloroquine was likely eliciting a range of
complicated effects in the cells it was difficult to attribute any changes in the IC50 values
between the cell lines to NQO2. A way to quantify the response cells had to combined
use of the drugs was needed to determine if any NQO2 dependent effect was occurring.
The works of Chou and Talalay on drug combination studies were consulted for this
purpose. The Chou-Talalay method they derived utilizes the median effect principle and
can allow one to calculate whether two or more drugs produce a synergistic, additive, or
antagonistic effect (117,125). This provides a standard for how drugs work in
combination and allowed for a better comparison between the cell lines used in this study
that express NQO2 or have the gene for the protein knocked out. In order to make such
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comparisons survival curves were generated for sunitinib, chloroquine and
sunitinib:chloroquine at equimolar doses after treating HCT116 cells for either 48 or
72hrs.
For both treatment times the HCT116NQO2+ cells were the most sensitive to
treatment with chloroquine alone (Figures 13(c,d),14(c,d)). When treated for 48hrs
NQO2 expression in the cells had no effect on the response to sunitinib treatment but a
significant effect was observed between HCT116NQO2+ and HCT1161ΔNQO2 when treated
for 72hrs (Figures 13(a,b),14(a,b)). Combining the drugs elicited no NQO2 dependent
effect when cells were treated for 48hrs but the 72hr treatment was more toxic to the
HCT116NQO2+ cells than is was to the knockout cells (Figures 13(e,f),14(e,f)). Applying
the Chou-Talalay method to the results showed that the greatest effect when the drugs
were combined for 48hrs occurred in the HCT1161ΔNQO2 cells which had an additive
interaction while the drugs acted antagonistically in the two other cell lines. Synergism
was observed between sunitinib and chloroquine when they were applied for 72hrs to
HCT116NQO2+ and HCT1161ΔNQO2 cells, the effect in HCT1162ΔNQO2 was closer to an
additive interaction.
Examining the effects of combined drug treatment with this method showed that
NQO2 was not relevant to the interactions that were occurring between the drugs. It also
demonstrated that the effects of combining the drugs were dependent upon the treatment
time. NQO2 may have no impact on the combined use of these drugs at equimolar
concentrations but it appears that NQO2 is relevant in determining cell response to
chloroquine treatment. Combination indexes should also be determined for different
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ratios of the drug combinations. The IC50 values of the drugs differ by about 5-8 fold so
conducting a combination treatment with 5:1 or 10:1 chloroquine:sunitinib may produce
a different effect.
It should also be noted that the IC50 values were about 2-fold lower in the 48hr
treatment group for all drug treatments when compared to cells treated for 72hrs.
Treatment time is thus likely an important determinate in the observed effect. The cell
culture experiments performed by Abdel-Aziz et al. showing synergism between the
drugs were conducted for 24hrs or 48hrs while their experiments on mouse models were
conducted for 6 days. In many of the cell lines they observed the greatest synergism at
the more acute treatment time (98). Li et al. conducted their combination drug treatments
with a fixed dose of chloroquine and varied sunitinib, thus complicating the matter of
determining the relationship between the drugs (99). Combining the drugs with different
treatment times may be necessary to see greater synergism and NQO2 dependent effects.
In their studies on the relationship between NQO2 with paraquat toxicity and autophagy,
Janda et al. observed the greatest effects when paraquat was administered for 7 days and
chloroquine was added to the treatment in the last hours of the experiment (49). This
suggests that very acute chloroquine treatment is sufficient to observe autophagy
inhibition and to elicit NQO2 mediated effects on cells. Further study of NQO2’s
contribution to drug combination should be conducted in additional cell lines with NQO2
knocked out and the mentioned variables should be altered to better characterize the
combined effects of sunitinib and chloroquine.
Colony formation assays were also performed in this study to assess the effects of
sunitinib and combination with chloroquine over a longer proliferation time period. HeLa
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and HeLaΔNQO2 cells were treated with a range of concentrations of sunitinib (0.2 – 200
µM) and either 0 µM chloroquine (Supplementary Figure 3(a)) or 10 µM chloroquine
(not shown). When chloroquine was not administered with sunitinib a significant
difference in colony counts was observed between the cell lines at doses of 0.78 and
3.125 µM sunitinib with HeLa cells being more sensitive to the former and NQO2
knockout cells more sensitive in the latter condition (Supplementary Figure 3(b)). All
cells given a dose of 10 µM chloroquine were killed and thus chloroquine combination
could not be examined.
The HCT116 cell lines were also used for colony formation assays. Cells were
treated with either 15, 3, 0.65, or 0 µM sunitinib in combination with either 0 or 2.5 µM
chloroquine. All cells treated with 15 µM sunitinib were killed before the end of the
experiment (Supplementary Figure 4(a)). In the 0 µM chloroquine group, HCT116NQO2+
cells were the least sensitive cell line when exposed to 3 µM sunitinib for 10 days and the
NQO2 knockout cells responded the same to treatment. Oddly, the HCT116NQO2+ cells
became more sensitive to treatment with 0.65 µM sunitinib though it is a lower dose and
may be due to high variation and low replicate number for the experiment, the knockout
cell lines had no difference from one another at this dose (Supplementary Figure 4(b)).
Combining sunitinib treatment with 2.5 µM chloroquine had no obvious impact.
HCT116NQO2+ cells were once again the least sensitive cell line when exposed to 3 µM
sunitinib and the HCT116ΔNQO2 cells were equally as sensitive. At a dose of 0.65 µM
sunitinib and 2.5 µM chloroquine the HCT1162ΔNQO2 cells faired slightly better than
control and had a significantly higher colony count compared to HCT116NQO2+ and
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HCT1161ΔNQO2 (Supplementary Figure 4(c)). The colony formation assays indicate that
the cells do have an NQO2 dependent response to sunitinib but experiments with higher
replicate number and more treatment concentrations should be performed to increase
confidence in results. No clear result from combined chloroquine treatment was
observed, as done by Janda et al. adding chloroquine only in the final hours of treatment
may be a better experimental setup to observed drug synergy and NQO2 dependent
effects (49).

4.3

Structure of NQO2 Bound to Sunitinib

Purified NQO2 protein crystallized fairly well and in a variety of conditions when
co-crystallized with sunitinib. Structures solved from data collected at the
Macromolecular crystallography facility at the University of Western Ontario had good
data quality but the density for much of sunitinib was missing from the datasets and only
the ring system of the drug could be seen (data not shown). Thus, it was decided that
crystals would be sent to CLS to collect higher resolution datasets for the NQO2sunitinib interaction. As can be seen from Figure 17 the density for sunitinib is very
apparent even after an initial refinement of the data collected from oxidized NQO2sunitinib crystals. The initial refinement of reduced NQO2-sunitinib had good density
over the isoalloxazine ring of the FAD molecules corresponding with where the planar
rings of drugs tend to sit when molecules bind NQO2 though the density for the reduced
structure was far less substantial than observed in the oxidized structure (Figure 21).
Overall, the fit for sunitinib into the refined structure of oxidized NQO2 was
much better than that for the reduced enzyme. Sunitinib bound to each active site in
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comparable orientations and at about the same depth into the active. In each active site
the ligand made interactions with 4 water molecules and the same 5 amino acid residues,
in addition to the stacking over the isoalloxazine ring of FAD (Figure 19). This indicates
that the observed density for sunitinib corresponds to one optimal binding motif of the
drug to the oxidized NQO2 protein.
Density for sunitinib was not as complete for the reduced NQO2 datasets thus
making the fitting of the ligand more difficult. The statistics for the fit of the drug in each
active site was less than desirable and fell below suggested correlation coefficients for
optimal ligand fits. In the reduced structure sunitinib was refined in two unique
conformations in the respective active sites. The first active site interaction is coordinated
by a “keystone water” characteristic of NQO2-drug interactions which facilitates a
hydrogen bond network with another two waters and two amino acid residues (6). In the
second active site sunitinib takes on a twisted conformation that disrupts one of the rings
in the drug which suggests the fit is not stable (Figure 23).
There are several possibilities to explain the refined reduced NQO2-sunitinib
structure. Firstly, the lower density for sunitinib could be explained by poor interactions
between the reduced enzyme and the drug. Kinetic studies would need to be done but the
case may be that sunitinib associates much more strongly with the oxidized state of the
enzyme and would thus explain the greater quality of the sunitinib fit in that structure. It
is also possible that sunitinib does bind to reduced NQO2 with considerable affinity but,
it does so in more than one orientation and would therefore make it more difficult to
resolve the density for the drug in the crystal structure. Multiple binding orientations have
been observed for the CK2 inhibitors TBBz and DMAT though the lower quality of
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sunitinib density and the greater size of the molecule would make the modelling difficult
(86).
Another factor to consider is the reduction of the NQO2-sunitinib crystal which
presents several challenges that may have impacted data quality and the NQO2-sunitinib
bond. The reducing soaks with SCDP may have interfered with sunitinib binding thus
resulting in poorer overall occupancy of sunitinib in the NQO2 active sites throughout the
crystals. Sunitinib was added to the reducing soaks, and a soak without any reducing
agent was done to help prevent SCDP outcompeting sunitinib for the active site but
refinement of these reducing soaks may be required for the best results. As mentioned, it
may also be that NQO2 is not getting fully reduced, the deep colour of sunitinib makes it
impossible to visually see the reduction of the NQO2 crystal as can normally be done for
reductions of the enzyme. Incomplete/inefficient reduction of the enzyme may be altering
its interactions with sunitinib and may explain the density observed from the x-ray data.
A different reduction protocol for NQO2-sunitinib crystals may need to be developed that
will allow for the monitoring of the reduction of the crystal and can confidently achieve a
reduced enzyme.
The different binding motifs of sunitinib to oxidized and reduced NQO2 were
further examined to investigate how the drugs interactions with the different states of the
enzyme may impact its function. The refined structures of oxidized and reduced NQO2sunitinib were superimposed and the active sites of the structures compared. In the first
active site of NQO2, sunitinib was found to bind deeper within the active site in the
reduced structure than it does in the oxidized structure (Figure 33(a,c,e)). Though in the
reduced structure the drug is deeper in the active site it also makes less contacts with the
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protein and binds to 1 fewer water molecule suggesting the interaction is not as strong.
When examining the superimposed structures for the second active site it can be seen that
the first two rings of sunitinib sit over the isoalloxazine rings in the same position in both
the oxidized and reduced structures (Figure 33(b,d,f)). Due to the breaking of a polar
bond between an oxygen and nitrogen in the reduced structure, the third ring normally
found in the sunitinib molecule is broken and the drug is in a twisted conformation that
overlaps poorly with the sunitinib molecule found in the oxidized structure. Overall, the
superimposed structures were found to have an RMSD of 0.758.
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Figure 33: Sunitinib Binds the Active Sites of NQO2 in Distinct Conformations
Based on the Redox Status of the Enzyme.
Superimposed refined structures for oxidized NQO2-sunitinib and reduced NQO2-sunitinib. Active site 1
(a,c,e) and active site 2 (b,d,f) shown from multiple angles in PyMOL. Oxidized NQO2, FAD and sunitinib
shown in green, yellow, and magenta respectively. Reduced NQO2, FAD and sunitinib shown in orange,
teal, and cyan respectively. Water molecules shown as red crosses and all other molecules displayed as a
stick diagram.

The NQO2-sunitinib structural data indicates that sunitinib binds to both active
sites of oxidized NQO2 in a conserved conformation, similar to what has been observed
for other NQO2 interacting drugs. A binding interaction unique to sunitinib was also
observed, namely a hydrogen bond network between the second oxygen atom in
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sunitinib, a water molecule and the G149, A191, and I194 residues (Figure 34(a,b)). At
least two different binding motifs were observed in the reduced structure that were
unique from what was observed in the oxidized structure. These may represent multiple
conformations possible for the reduced NQO2-sunitinib interaction though one of the
orientations for sunitinib breaks planar restraints for the drug and may not be a stable
interaction observed in solution. The other orientation for the reduced structure places
sunitinib slightly deeper in the active site. This result runs contrary to what was observed
for NQO2-DMAT structures where the drug was not as deep in the binding site in the
reduced structure (86).

Figure 34: Sunitinib Binds the Active Sites of Oxidized NQO2 Through Unique
Contacts with the Enzyme.
Hydrogen bond network unique to the oxidized NQO2-sunitinib structure. Amino acid residues G149,
A191 and I194 are displayed as blue, sunitinib shown as magenta and water molecules represented as red
cross in active site 1 (a) and active site 2 (b) respectively. Molecules depicted as stick representations in
PyMOL.
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4.4
Mass Spectrometry of HCT116NQO2+ and
HCT116ΔNQO2 Cells Identifies Novel Proteomic Changes
and Potential Regulatory Roles for NQO2
The study of roles for NQO2 beyond quinone detoxification has revealed
interesting possibilities for how the protein functions but much of the evidence is not
concrete or requires further confirmation. For example, studies that have shown NQO2
can protect p53 from degradation through interactions with the 20S proteasome required
the addition of NRH to cells to observe the effect (44). Given the uncertainty surrounding
NRH levels in cells it remains questionable if NQO2 can protect p53 under physiological
conditions. Research into NQO2’s role as the third melatonin binding site has proved to
be more useful for studies of the kinetics of NQO2 enzymatic activity (due to the
development of the NQO2 specific inhibitor S29434) than it has for determining
melatonin related signaling roles for the protein (48,56,63).
Identifying NQO2 signaling functions is relevant to understanding the effects of
NQO2 binding with clinical drugs. The evidence indicates that many drugs that have
been found to bind to NQO2 do not act as substrates and instead result in inhibition of
NQO2 enzymatic activity through competition with either NQO2 substrates or cosubstrates for the active site (81,86). Attempts to promote NQO2 reduction of interacting
drugs have been carried out, through adding NRH to cells treated with various drugs, and
there was no indication that NQO2 was altering the toxicity of these drugs through an
enzymatic reaction (101). Thus, it remains probable that NQO2 contributes to the effects
of drugs it interacts with through unidentified signaling events.
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To gain a gain a better insight into potential regulatory roles for NQO2, label free
mass spectrometry was employed. This technique was chosen as it would provide us with
a broad landscape to examine, namely the proteome, and allow us to analyze how NQO2
contributes to the composition of it. It could also allow for the identification of the factors
that contribute to the attenuated proliferation rates observed in NQO2 knockout cells
(101,120). The HCT116 cell lines generated by Kevin Leung in his thesis, and used
throughout this study, were chosen to examine by whole cell label free mass spectrometry
(101). These were chosen over the HeLa cells as we have two NQO2 knockout lines for
the HCT116 cells, comparing the results from these cells would serve as a good control to
filter out changes to the proteome that are a result of random differences between the
lines that may have resulted from the gene knockout process. It also allowed us to
examine only the differences in the proteomes, compared to HCT116NQO2+ cells, that
occurred in both lines and could more confidently be attributed to NQO2.
The mass spectrometry results presented in this thesis are the first insights into
NQO2 regulation of the proteome and provides many avenues for future research. A
similar experiment should be conducted on additional cell lines such as the HeLa cells
utilized in this study to validate the results and determine cell line dependent differences.
Corroborating the results presented in this thesis in other cell lines would bolster support
for the potential regulatory roles proposed herein. Label free mass spectrometry can also
be used to look at proteomic differences between NQO2 expressing cells and NQO2
knockout cells cultured in a variety of conditions. The cells examined in this project were
cultured under normal culturing conditions for the cell line. Cells should also be
examined when exposed to doses of NQO2 interacting drugs or when culture medium is
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supplemented with various levels of exogenous NRH. Such experiments would advance
the understanding of how NQO2 interacts with such drugs and how the redox state of
NQO2 regulates the proteome.
As it stands, we propose that NQO2 has regulatory roles related to influencing the
expression levels of various exosome and lysosome associated proteins, as well as
proteins associated with other cellular functions that will be detailed. The extensive
changes in the proteomes between HCT116NQO2+ cells and HCT116ΔNQO2 cells is
consistent with the hypothesis that NQO2 can regulate proteins through flavin redoxswitch function. Functional enrichment analysis has provided avenues to study NQO2’s
function pertaining to the regulation of various cellular functions. This study has
demonstrated that exosomes can be successfully isolated from the HCT116 cell lines used
herein, the current isolation technique indicates that exosomes are produced at far lower
quantities in HCT116ΔNQO2 cells (Figure 31). The expression levels observed in the mass
spectrometry experiment have been validated for a candidate protein with large
differences in expression between HCT116NQO2+ cells and HCT116ΔNQO2 cells. The
expression of CD73 was validated by western blot and correlated with the observation
from the mass spectrometry data (Figure 32). Additional proteins should be examined to
validate the expression levels in cells and experiments designed to test NQO2’s
contribution to various cellular functions.

4.4.1

Exploring Mass Spectrometry Data with Bioinformatics
Each cell line had an average of about 4600 detectable proteins in the

experimental setup (Figure 25(a)). There was also good overlap in the proteins that were
detected with 4677 proteins being quantified in at least one sample for each cell line
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(Figure 25(b)). Having overlap between the groups is important for analysis because it
provides for a large landscape of data that can be analyzed and the difference between the
groups examined.
Due to the probabilistic nature of protein detection by mass spectrometry and
variation between runs the lack of protein identification in one group vs another (i.e.
HCT116NQO2+ vs HCT116ΔNQO2) may not be representative of a biological difference in
the cell lines (126). However, the use of 5 biological replicates and two different NQO2
knockout cell lines increases the confidence that if a protein was not detected in
HCT116NQO2+ cells but was in HCT116ΔNQO2 cells (or vice versa) it can be attributed to
lack of or very low expression of that particular protein. The observation that NQO2 was
quantified in the HCT116NQO2+ cell line and neither of the knockout cell lines is a good
indicator of the quality of the data and further confirms the successful knockout of the
gene for NQO2 (Figure 25(c)). Conclusions about the cell lines informed by the rest of
the proteins listed in Figure 25(c) should be made hesitantly given the stated uncertainty
and the “missing value problem” but may be worth investigating in future studies
(126,127). Proteins from that list were retained in analysis by estimating LFQ values
using a normal distribution for the dataset.
The principal component analysis performed in Perseus was used to see how
varied the proteomes of each sample were and to gain an insight into what factors were
responsible for the variation (128). Though not an empirical piece of data in itself the
principal component analysis revealed complete segregation of the HCT116NQO2+ samples
from the HCT116ΔNQO2 samples along the first principal component (Figure 26). This
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level of statistical analysis is useful because, it demonstrates the distinct proteomic
profiles of the NQO2 expressing cells and the cells that no longer express the enzyme.
The gene names for the proteins that were most responsible for the variation in the data
were; LMNA, PKM, EZR, ACTG1, AHNAK, and PLEC.
The volcano plots displayed in Figure 27 summarize the results of statistical
analysis between each group of cell lines. The lists of proteins with significant changes
between the cell lines were generated from this analysis. Statistical analysis of the data
demonstrated that the proteomes of the two HCT116ΔNQO2 cell lines were very similar to
one another. Just 11 proteins were found to have mean LFQ values that were statistically
distinct between the two cell lines (Figure 27(c)). Compared to the plots for
HCT116NQO2+ vs HCT1161ΔNQO2 and HCT116NQO2+ vs HCT1162ΔNQO2, which had totals
of 173 and 162 proteins with significantly different relative quantification values
respectively (Figure 27(a,b)), it is clear that the knockout cell lines have proteomes that
are distinct from NQO2 expressing cells but very similar to one another.
The lists of proteins with significant differences were taken and the proteins in
common to both the HCT116NQO2+ vs HCT1161ΔNQO2 and HCT116NQO2+ vs
HCT1162ΔNQO2 groups were determined. The complete lists of the proteins in common
between these groups that had significantly higher or lower mean LFQ values in
HCT116NQO2+ are displayed in Supplementary Tables 1 and 2 along with the foldchange in abundance. The CD73 Protein had a significantly lower mean LFQ in the
HCT116NQO2+ cells with about a 16.4 and 25.5 fold difference compared to the respective
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knockout cell lines. The expression of the protein in the cell lines was validated by
western blot and will be discussed in greater depth in a later section.
A notable protein with a significantly greater mean LFQ value in the
HCT116NQO2+ cell line is caveolin-2 (CAV2). As discussed in section 1.3.3 an association
between NQO2 and CAV1 was recently reported by Dorai et al. in 2018 (50). CAV1 was
detected in each cell line in the mass spectrometry experiment but the differences in LFQ
values between the cells was not significant. CAV2 however had about 6.6 and 2.5 fold
greater abundance in HCT116NQO2+ cells when compared to each of the NQO2 knockout
cell lines. The finding that CAV2 expression is impacted by NQO2 and the functional
enrichment analysis revealing significant enrichment of exosome and extracellular
vesicle associated proteins indicates that NQO2 has roles in the regulation of their
formation and or secretion (Figures 28(c), 29(a), 30).
CAV2 helps to promote the formation of caveolae and is dependent upon
interactions with CAV1, which it is co-expressed with, to achieve proper localization
(129). In addition to caveolae formation CAV2 has defined roles in lipid rafts, lipid
metabolism and the permeability of the blood brain barrier (130). A worthwhile avenue to
research in the future would be to investigate how NQO2 mediates the relationship
between CAV1 and CAV2. NQO2 has already been shown to interact with CAV1 and
has an impact on extracellular vesicle formation, it is thus likely that NQO2 influences
CAV2 function given the close relationship between CAV1 and CAV2 (50,129).
At least two studies have demonstrated that interactions between NQO2 and
resveratrol can shift cells away from glycolysis dependency. In one instance Janda et al.
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reported decreased usage of glucose and greater oxidative phosphorylation when cells
were treated with resveratrol or the NQO2 specific inhibitor S29434 (131). Resveratrol
and NQO2 have also been implicated in increasing the turnover of c-myc and may be
exploitable to prevent the reprogramming of cancer cells towards glucose addiction
(132). It is therefore intriguing to observe that the HCT116NQO2+ cells have significantly
higher expression levels – at least 10 times greater – of glucose transporter protein type 1
(GLUT1) (Supplementary Table 1). If the NQO2 knockout HCT116 cells have
intrinsically lower levels of GLUT1 they likely have lower basal glucose utilization. This
would correspond with the findings reporting inhibition of NQO2 with resveratrol
impacts glucose metabolism (131,132). Glucose utilization may be a factor in the
attenuation of proliferation observed in NQO2 knockout cells. GLUT1 expression in the
HCT116 cell lines should be explored under different conditions, such as treatment with
resveratrol or other NQO2 interacting drugs, to determine NQO2’s contribution to its
expression.

4.4.2

Revelations from Functional Enrichment Analysis
The mass spectrometry data, once sorted into groups of proteins with significant

differences in LFQ values, was further investigated by functional enrichment analysis.
Functional enrichment analysis was performed through two distinct workflows for
comprehensive analysis of the dataset. The first workflow comprised of uploading the
gene lists of proteins with significant changes between the cell lines into FunRich. The
default human database in the program was used as the background for enrichment
analysis (112). A combination of g:Profiler and Cytoscape was used for the second
enrichment analysis, adapting a workflow described by Reimand et al. and using the set
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of all proteins identified in the mass spectrometry experiment as the background for the
analysis (133).

4.4.2.1

Functional Enrichment Analysis Using FunRich

Enrichment analysis in FunRich revealed disproportionate enrichment of proteins
associated with exosome function (in the set of proteins with greater abundance in the
NQO2 expressing cell line) and lysosome function (in the set of proteins with decreased
abundance in the NQO2 expressing cell line) (Figure 28(c,d)). The gene names for the
proteins categorized as having exosome or lysosome function are listed in
Supplementary Table 4.
Exosomes and lysosomes have overlapping functions in regards to cellular
recycling/degradation of proteins and other molecules such as RNA (134). Multivesicular
bodies (MVBs) are the node at which lysosomes and exosomes interact, the targeting of
contents of MVBs to lysosomes leads to degradation while fusion of portions of MVBs to
the plasma membrane can result in exosome formation and subsequent secretion of
contents in the small vesicles (135,136). Lysosomes and exosomes also have roles in
microautophagy and act downstream of macroautophagy (137).
It is intriguing that proteins associated with exosomes and lysosomes are enriched
in the mass spectrometry results as it may explain the connections between NQO2 and
autophagy. NQO2 has been implicated in regulating autophagy in multiple publications
and it has been speculated that NQO2 interactions contribute to chloroquine inhibition of
autophagy beyond the chemical effects of the drug (49,64,138). The results described by
Janda et al. seem to indicate NQO2 inhibition promotes autophagic flux and alleviates
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stalling of autophagy at the stage of autophagosome and lysosome fusion when cells are
treated with paraquat (49). Major prion protein (PRNP) has been demonstrated to affect
autophagic flux in neuronal cell lines exposed to oxidative stress and the mass
spectrometry results presented in this thesis suggest PRNP levels are influenced by
NQO2 (139). PRNP was detected exclusively in the HCT116ΔNQO2 cell lines and not
HCT116NQO2+, after filling in the missing LFQ values with estimates from the normal
distribution of the dataset the predicted LFQ values for the protein in HCT116NQO2+ cells
were significantly lower from the quantification values for PRNP in the NQO2 knockout
cell lines (Figure 25(c) and Supplementary Table 2). Thus, NQO2 modulation of
autophagy may in part be explained by the protein’s influence on PRNP expression
levels.
If NQO2 is regulating autophagy the evidence from Janda et al. and the mass
spectrometry results presented in this project suggest it does so by affecting
autophagosome fusion to lysosomes (49). Another protein that was found to have
pronounced differences in expression between the HCT116 cell lines was Rab23, with
2.26 and 2.4 times lower average LFQ values in HCT116NQO2+ relative to each of the
knockout cell lines (Supplementary Table 2). Rab23 is present on both autophagosomes
and lysosomes and there is evidence to support a role for the protein in the fusion of these
two vesicles (140,141). The opposing effects of paraquat and S29434 reported by Janda
et al. would be consistent with a flavin-redox switch function for NQO2 (49). If NQO2 is
a regulator of autophagy it may be dependent upon the redox status of the protein and the
effects NQO2 appears to have on the levels of the proteins highlighted in the mass
spectrometry results.
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FunRich was also used to determine what proteins with significant changes have
been identified as cargo or components of exosomes and extracellular vesicles.
Vesiclepedia is a comprehensive database for the study of all types of extracellular
vesicles and contains curated data on the molecular composition of various vesicles in
different states (142). The candidate proteins identified in the mass spectrometry
experiment were compared with the vesiclepedia database filtered for entries of proteins
found in exosomes or extracellular vesicles. About 80% of the candidate proteins
impacted by NQO2 expression matched to entries in the vesiclepedia database (Figure
35). The composition of exosomes from the HCT116 cell lines is an avenue to pursue for
future research.

Figure 35: Majority of Proteins with Significant Changes in Abundance Between
HCT116NQO2+ Cells and HCT116ΔNQO2 Cells have been Identified as Cargo in
Exosomes and Extracellular Vesicles.
Venn diagram of proteins determined to have significantly different LFQ values between HCT116 NQO2+
cells and both HCT1161ΔNQO2 and HCT1162ΔNQO2 with proteins in the vesiclepedia database. Vesiclepedia
database was filtered to include proteins that have been observed as cargo in exosomes or extracellular
vesicles. 84 proteins from the mass spectrometry experiment with significant changes have also been
proven to be cargo of the stated vesicles.
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4.4.3

Functional Enrichment Analysis using g:Profiler and
Cytoscape
Whereas FunRich uses a background for enrichment analysis that consists of

annotations for all human genes and proteins pulled from a variety of databases g:Profiler
can be used with a custom background (112,133). The complete list of proteins identified
by label-free mass spectrometry in this study was uploaded to be used as the background
for enrichment analysis of the significant proteomic differences between HCT116NQO2+
and HCT116ΔNQO2 cells. There are a number of variables that bias which proteins are
likely to be identified by LC-MS/MS experiments, for instance more abundant proteins
have a higher likelihood of being selected and quantified on any given run of a sample
(143). By performing an additional enrichment analysis using the more constrained
background, information can be learned about what functions are enriched in the
proteomic changes amongst the proteins that were possible to be quantified in the
experimental setup (133).
Functional enrichment analysis reports for the set of proteins with greater mean
LFQ values in the HCT116NQO2+ cell line, lower mean LFQ values in the HCT116NQO2+
cell line and all proteins with significant differences in abundance between the cell lines
were generated. The enrichment analyses were then imported into Cytoscape where
interaction networks were created using the EnrichmentMap and AutoAnnotate
applications (133). There was redundancy in the enrichment analysis as many proteins
were grouped with multiple related functions so the clustering of functions helped to
summarize the network and give an overview of the significant proteomic changes that
were observed.
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Overall, this enrichment analysis tells a similar but more detailed story than the
FunRich analysis. The group of proteins with greater abundance in HCT116NQO2+ are
disproportionately associated with a variety of membrane functions, vesicles and
extracellular roles. The proteins with decreased LFQ values similarly are
disproportionately membrane anchored proteins. Results of the functional enrichment
analysis are summarized in Supplementary Tables 5, 6, and 7 and show the gene names
of the proteins sorted into the listed functions.
Caveola proteins were a significantly enriched group amongst the proteomic
changes. In addition to the mentioned CAV2 protein, GLUT1 and EH domain-containing
protein 2 (EHD2) were grouped to caveola. Research has shown GLUT1 can localize to
the caveola membrane and can facilitate glucose metabolism in these vesicles (144). The
tethering of caveola to the plasma membrane has been shown to be controlled by EHD2
which facilitates connections between the vesicles and actin filaments. ATP and
oligomerization of EHD2 are required for the process to occur and switching between on
and off states of the protein appears to control whether caveola are tethered to the
membrane or are trafficable (145). The proteomics indicate that NQO2 influences the
expression of a variety of proteins that have actin binding function in addition to EHD2.
It remains unclear how NQO2 factors into caveolae function but, the evidence presented
in this thesis taken together with the observations by Dorai et al. point towards roles in
regulating the formation of caveolae and subsequently extracellular vesicles (50).
Drawing concrete conclusions in regards to cellular functions for NQO2 is not
appropriate from the mass spectrometry experiment and enrichment analysis alone.
Validation of the expression levels of the identified proteins is necessary and experiments
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must be performed to more directly link NQO2 to the proposed functions. The power of
the results depicted in this thesis will be in corroborating findings from existing and
future publications. It will also allow for better informed experimental design in the study
of NQO2 functions relevant to cellular contexts. The results also provide support for the
hypothesis that NQO2 functions primarily as a regulator through flavin-redox switch
function rather than the presumed enzymatic function of the protein.

4.5

NQO2 and Exosomes

Exosomes are small extracellular vesicles (about 30-100 nM in diameter) that
arise from MVB fusion with the plasma membrane (146). The term exosome was coined
in 1981 by Trams et al. from a study of CD73 activity in secreted vesicles of
neuroblastoma cell lines from mice and were notable for there small size and the presence
of the 5’-ecto-nucleotidase on their lipid membrane (147). Since then exosomes have
come to be an intriguing field of study for their roles in immune response, intercellular
communication, autophagy and cancer progression (134,136,137,146). Exosomes have
highly variable cargo of proteins, miRNAs, and mRNAs that are dependent on cell type
and on cellular conditions (148). There are however, common components responsible
for the biogenesis of the vesicles and their function. A range of tetraspanins, such as
CD9, are commonly associated with exosomes and crucial for their function (136,149).
Proteins associated with membrane transport, cytoskeleton maintenance, antigen
presentation and certain enzymes are also common features of exosomes (146).
Identification of the cargo of exosomes is commonly done, through RNA
sequencing experiments or proteomics, in order to understand the function of the secreted
vesicles given the cellular contexts (150). NQO2 for instance has been identified as cargo
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in exosomes extracted from a variety of cancer cell lines and in exosomes isolated from
urine samples (151,152). Exosomes are thought to play key roles in cancer as cell-cell
signaling vesicles and the establishment of extracellular environments conducive to
cancer development or colonization by metastasis (153,154). Thus, isolating exosomes
and identifying their contents has become a common practise for determining factors that
drive disease progression or finding exploitable biomarkers for diagnostic purposes
(146).
In this study, exosomes were successfully isolated from the HCT116 cell lines via
an ultracentrifugation method to demonstrate that exosomes could be purified from the
cell lines used in the mass spectrometry experiment. The amounts of CD9 in the
extracellular vesicle samples collected from the HCT116ΔNQO2 cells was either very low
or not detectable (Figure 31(b)). CD9 was much more abundant in the sample collected
from HCT116NQO2+ cells and would indicate that either a greater proportion of exosomes
were present in the pellet remaining after ultracentrifugation or that exosomes from that
cell line have more CD9 on their membrane. The LFQ values of CD9 were comparable
across all the cells lines in the label-free mass spectrometry experiment so there is no
indication the lower levels of CD9 on HCT116ΔNQO2 exosomes would be a result of lower
expression generally in the cells, though this could be assessed by western blot. A more
comprehensive study of the exosomes secreted from the HCT116 cell lines should be
conducted to better understand how NQO2 influences the amounts of exosomes produced
and their composition. If HCT116ΔNQO2 cells do have impaired exosome function then
treating HCT116NQO2+ cells with NQO2 interacting drugs may result in the attenuation of
exosome secretion comparable to the knockout cells and thus implicate NQO2 in
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regulating exosome secretion. The induction of autophagy has been found to act against
the formation and secretion of exosomes, higher basal rates of autophagy in the NQO2
knockout cells may be responsible for the apparent decrease in exosome secretion (155).
Since a disproportionate amount of exosome associated proteins accounted for the
proteomic differences between HCT116NQO2+ and HCT116ΔNQO2 cells it seemed a logical
choice to examine the exosomes of the respective cell lines in follow up research. Though
widely used, the ultracentrifugation method for purification of exosomes is relatively
crude and not as specific as other methods such as flow cytometry or immunocapture
(148). Therefore, if the study of NQO2’s relationship to exosomes is to be pursued it
would be beneficial to adopt a more robust exosome purification method for the HCT116
cells used in this study. Characterizing the contents of the exosomes secreted from these
cell lines would be a worthwhile endeavor and could be accomplished with RNA
sequencing experiments or with mass spectrometry to identify and quantify protein
contents.

4.6
Differences in CD73 Expression in HCT116NQO2+
Cells and HCT116ΔNQO2 Cells
CD73 is a GPI-anchored protein found on a variety of different membranes in
human cells and is responsible for extracellular adenosine production as an ecto-5’nucleotidase (156). It works in concert with the CD39 protein which catalyzes conversion
of extracellular ATP/ADP into AMP, CD73 subsequently converts the mononucleotide
into adenosine. The extracellular adenosine generated by CD73 facilitates adenosine
signalling through adenosine receptors found on the membranes of cells (119). CD73 is
particularly notable for its roles in immune regulation. Populations of T regulatory cells
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with membrane bound CD39 and CD73 play important roles in immune suppression,
through the binding of adenosine produced from these cells to adenosine receptors on T
effector cells (157). Though the immune suppressive roles of CD73 are important to
regulating immune response this function can be detrimental in cancer development. It
has been shown that mice with CD73 knocked out were more resistant to developing
various tumors when injected with the respective cancer cells and, also lead to impaired
metastasis (158). The immune suppressive function of CD73 has been shown to be
exploited in some cancers as well. Clayton et al. examined exosomes secreted by several
cancer cell lines and found all to be double positive for both CD39 and CD73. They also
demonstrated that exosomes isolated from the cell lines could produce adenosine from
ATP and could induce signalling responses in T cells that were consistent with supressing
immune function (159). These results indicate that the immune suppression facilitated by
CD73 creates an extracellular environment conducive to cancer development and
exosome secretion combined with increased CD73 expression is a strategy employed by
some cancers to establish a niche.
The mass spectrometry experiment revealed that CD73 was far less abundant in
the HCT116NQO2+ cells than it was in the HCT116ΔNQO2 cell lines. Amongst the group of
proteins with decreased LFQ values in HCT116NQO2+ CD73 had the greatest fold change
in abundance between the NQO2 expressing cells and the knockout cells
(Supplementary Table 2). Expression levels of CD73 were confirmed by western blot in
the three HCT116 cell lines and corresponded with what was observed in the proteomics
(Figure 32). These results indicate that NQO2 has a suppressive role in regulating CD73
expression as it is present at far lower quantities in the HCT116NQO2+ cells. An attempt

132

was made to assess CD73 levels in the exosomes collected from the respective cell lines
but it could not be detected in any of the samples (data not shown). A variety of CD73
activity assays could also be used to determine the enzymatic activity of CD73 in each of
the cells.
Inhibiting CD73 activity has been studied as a possible avenue for cancer
treatment. Extracellular adenosine production promotes both the suppression of immune
response to cancer cells and promotes angiogenesis at the site of tumors. Research has
demonstrated that inhibition of CD73 is effective at preventing angiogenesis in mouse
models of cancer, implicating extracellular adenosine in cancer progression (160). Small
molecule inhibitors, such as α,β-methylene-ADP (APCP), have been developed as a
means to pharmaceutically inhibit the ecto-5’-nucleotidase and may prove to be effective
for clinical use (161). A point to consider would be the impact that NQO2 interacting
clinical drugs have on CD73 levels. If NQO2 is in fact a regulator of the expression of
CD73 then the binding of kinase inhibitors or other drugs to NQO2 may be contributing
to immunosuppressive effects in addition to the effects produced from interacting with
their primary target. Results from our HCT116 cell lines indicate that the lack of NQO2
expression leads to greater expression of CD73 and thus an increased potential for
immune suppression.

4.7

Future Directions and Concluding Remarks

The findings from this thesis project opens the door for numerous avenues of
NQO2 research in the future. Integration of the data from the varied experimental
approaches utilized herein, will aid in ascertaining the biological functions of NQO2.
Cellular biology experiments using NQO2 expressing and NQO2 knockout cells allows
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for studies comparing the response of the cells when subjected to a range of treatments or
culturing conditions. In this project the response of such cell lines was compared when
treated with a variety of NQO2 interacting clinical drugs. Along those lines determining
the structure of NQO2-drug complexes is important to have a full view of the binding
motifs of NQO2 interacting drugs and the impacts they have on the conformation of
NQO2. Unique modes of binding to NQO2 or preferences for either the oxidized or
reduced state likely have great impacts on how cells respond to treatment with drugs that
bind to NQO2. Proteomic approaches for investigating NQO2 function should also be
pursued in greater depth. This project revealed that NQO2 has extensive impacts on the
proteome, particularly on lysosome and exosome associated proteins in HCT116 cells. If
NQO2 is a flavin-redox switch it would be expected that the proteome would be altered
in an NQO2 dependent manner when cells are subjected to different redox states or when
NQO2’s conformation is modulated by drug binding.
Several NQO2 dependent effects of clinical kinase inhibitor drugs were observed.
Namely the increased sensitivity of HeLaΔNQO2 cells to TBBz and DMAT appears to be
linked to greater levels of apoptosis in those cells, compared to HeLa cells that express
NQO2, an effect that may be regulated by NQO2 and thus should be examined with
greater depth (Figures 5 and 6). The effects of NQO2 modulation of apoptosis should be
examined more broadly, beyond the reported impact NQO2 may have on p53 stability
(44,45).
Pacritinib was also notably more toxic to HCT116ΔNQO2 cells and its impact on
NQO2 should be investigated further (Figure 16(a,b)). Oxidized NQO2 structures for
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both pacritinib and crenolanib binding have been solved however, examination of their
potential interactions with the reduced state of the enzyme have not been conducted and
would be worth elucidating (92). The same would hold true for all other NQO2 binding
drugs presently known or yet to be identified, the capacity for NQO2 to switch between
oxidized and reduced states is fundamental for its enzymatic activity but is also crucially
relevant for signalling roles mediated by flavin-redox switch action. Thus, any analysis of
NQO2 interactions with drugs should consider how the redox state of the protein factors
in.
Investigation of sunitinib’s interaction with NQO2 revealed distinct differences in
how the drug binds to oxidized and reduced NQO2. The mode of binding to oxidized
NQO2 was conserved in each active site of NQO2 and made unique contacts with the
enzyme not observed in structures of NQO2 bound to other drugs (Figures 19 and 34).
Sunitinib interacted with the reduced state of NQO2 by binding deeper in the active site
of the protein though with fewer residue contacts (Figure 23). The multiple modes of
binding observed in the reduced structure could indicate more conformations of NQO2sunitinib interactions are possible in reducing environments or that a fully reduced state
was not achieved. The nature of sunitinib’s interactions with oxidized and reduced NQO2
should be clarified with kinetic studies or through isothermal titration calorimetry to
determine the affinity sunitinib has for each state of NQO2.
Sunitinib was slightly more toxic to HeLa cells than it was to HeLaΔNQO2 cells
when toxicity was assessed via SRB assay (Figure 15(e,f)). Using an MTT assay did not
yield the same results nor did either assay conducted on HCT116 cells show any
difference between NQO2 knockout cell or NQO2 expressing cells. Conflicting results
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were observed when cells were treated with both chloroquine and sunitinib in a test of the
synergism of the drugs. When toxicity was measured by an MTT assay and chloroquine
was administered at a constant dose the HCT116ΔNQO2 cell lines were the most sensitive
to sunitinib (Figure 12). However, when sunitinib and chloroquine were administered at
equal concentrations for 72hrs the HCT116NQO2+ cell line was the most sensitive to
treatment (as measured by SRB assay), though similar levels of synergism were
calculated in the NQO2 knockout cells (Figure 14(e,f)).
The differences between what the MTT assays and the SRB assays are measuring
must be considered and could explain the differences in the observed results. In the MTT
assay the aforementioned compound is reduced to formazan crystals by metabolic
enzymes in the mitochondria. Thus, measuring the absorbance of the formed formazan
reflects the overall activity of the mitochondria of the cells remaining at the end of the
experiment in each condition (103). The SRB dye on the other hand is a protein stain that
will bind to the total protein of cells fixed to plates and has been reported to have better
sensitivity compared to MTT (102). A greater degree of variability was observed
generally when performing cell viability assays that were measured via MTT rather than
with SRB. Greater sensitivity at lower cell densities and lower variation is desirable for
the toxicity assays conducted, particularly as the NQO2 dependent effects appear to be
rather subtle.
NQO2 may also be confounding the results of MTT assays. Reduced substrates of
NQO2 are capable of performing non-catalytic reductions of MTT, forming formazan
crystals (47). The assumption that NQO2 is functionally a dead enzyme in cells unless
provided with exogenous co-substrates was made but it is possible there is some latent
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enzymatic activity that could contribute towards the reduction of MTT that would not
occur in the NQO2 knockout cell lines. The mass spectrometry results also provide
evidence for indirect NQO2 dependent changes to metabolic activity. Though a
significant enrichment was not observed, there were many proteins related to
mitochondrion function and metabolism that had significant changes in LFQ values
between the HCT116NQO2+ cell line and the HCT116ΔNQO2 cell lines. Some examples are
Cytochrome c oxidase subunit 7A2, Monocarboxylate transporter 1, 2,4-dienoyl-CoA
reductase, Methylcrotonoyl-CoA carboxylase beta chain, and Calcium-binding
mitochondrial carrier protein Aralar2 all of which had significantly lower mean LFQ
values in the HCT116NQO2+ cell line (Supplementary Table 2). Given the stated
concerns and considerations regarding the use of MTT as a surrogate of cell viability for
experiments concerning NQO2 function, its use as a reagent should be avoided were
possible in the future. The SRB assay should be utilized moving forward when
comparing the toxicities of NQO2 interacting drugs in NQO2 expressing and NQO2
knockout cell lines to avoid the possible confounding variables of approaches that
measure metabolic activity.
Though NQO2 dependent synergism between sunitinib and chloroquine was not
observed there was a pronounced effect of NQO2 expression on the toxicity of
chloroquine. Whether treated for 48 or 72 hrs, HCT116NQO2+ cells were the most
sensitive to treatment with the antimalarial drug (Figures 13 and 14(c,d)). This
observation gives credence to the idea that NQO2 is a contributing factor to the effects
observed from chloroquine treatment. The commonly accepted mechanism for
chloroquine function is that it inhibits autophagic flux by acting as a base in lysosomes,
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thus de-acidifying the organelles and impairing autophagosome and lysosome fusion
(162). Though the majority of its effects may be attributable to its chemical nature, as the
only known human protein that interacts with chloroquine, NQO2 should not be
discounted in playing a role in chloroquine treatment (80).
Our mass spectrometry results show that NQO2 dependent changes in the
proteome are largely comprised of lysosome associated proteins, indicating NQO2 has a
regulatory role in the function of the organelles and thus autophagic flux. A study by
Gallagher et al. reported that the development of resistance to chloroquine can be
attributable to glucose deprivation in cancer cells (163). A possible explanation for the
greater tolerability of NQO2 knockout cells to chloroquine treatment may be due to an
impaired ability to utilize glucose as mentioned when discussing the lower expression
levels of GLUT1 in the HCT116ΔNQO2 cell lines. Regardless, the results of this thesis
support a role for NQO2 in the regulation of autophagy and the mechanistic action of
chloroquine. The autophagic capacity of the HCT116 cells used in the study should be
studied in greater depth to determine if NQO2 has roles in the pathway. This could be
accomplished by utilizing markers for autophagy such as LC3, Beclin, and LAMP
proteins, the papers published by Janda et al. would be good resources for devising
experiments for studying NQO2 regulation of autophagy in our HCT116 cell lines
(49,66,164).
Conducting proteomics experiments to identify changes between the
HCT116NQO2+ cells and the HCT116ΔNQO2 cells when treated with either primaquine or
chloroquine would be revealing experiments to conduct as well. Primaquine binds to
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NQO2 preferentially when the protein is in the oxidized state while chloroquine has
greater affinity for the reduced state (6). This experiment would not only highlight how
NQO2 mediates the actions of each of these drugs but it may also demonstrate the flavinredox switch function of NQO2 as different changes in the proteome would be expected
depending on which redox state of the protein the drug interacts with.
NQO2 regulation of exosome secretion, function and composition is a novel role
for NQO2 revealed from the proteomics in this study and supported by a previous study
by Dorai et al. linking NQO2 to extracellular vesicles (50). It was demonstrated that
exosomes can be collected from the cell lines used in this study though more refined
protocols should be employed in the future if this avenue of research is to be followed.
As it stands, HCT116NQO2+ cells appear to either secrete more exosomes or have more
CD9 marker on their membranes.
To conclude, this thesis project furthered the knowledge of NQO2’s cellular
functions by determining cellular toxicity of NQO2 interacting drugs, solving x-ray
crystal structures of NQO2 bound to a clinical kinase inhibitor in each of its redox states
and identifying proteomic differences between NQO2 expressing and NQO2 knockout
cells. Several drugs that bind to NQO2 demonstrated differences in toxicity dependent
upon NQO2 expression, results that could contribute to forming a more comprehensive
picture of the mechanism of such drugs. The structures of NQO2 bound to sunitinib
supports a flavin-redox switch function for the enzyme as different modes of binding
were observed between the oxidized and reduced structures similarly to what has been
observed with other drugs. NQO2 was also linked to proteomic regulation, particularly of
the lysosomes and exosomes. The mass spectrometry data reported in this thesis can be
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utilized as a resource for testing novel roles for NQO2. Expression of CD73 has been
confirmed to be drastically lower in HCT116NQO2+ cells than it is in HCT116ΔNQO2 cells
and may point towards roles for NQO2 in immune responses. The expression of the other
proteins highlighted in the proteomics should be validated. Though this thesis does not
confirm NQO2 functions as a flavin-redox switch or definitively prove any regulatory
roles for the peculiar enzyme, the results reported herein are consistent with the
hypothesis and provides new avenues for the testing of the protein’s function.
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Supplementary Figures/Tables

Supplementary Figure 1: Chemical Structures of NQO2 Interacting Drugs.
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Supplementary Figure 2: CK2 inhibitors induce apoptosis in a time and dose
dependent manner, NQO2 interacting CK2 inhibitors are most potent to cells.
Western blot (a) for PARP and cleaved PARP as a marker for apoptosis. HeLa and HeLaΔNQO2 cells were
seeded in 6-well plates and cultured until reaching 80% confluency. Cells were treated with either 8µM or
50µM of TBB, TBBz or DMAT. Treatments were conducted for 18hrs, 24hrs, or 48hrs at which point cells
were collected and samples prepared for western blotting. Ratio of Cleaved PARP signal to PARP signal
was determined for each treatment condition on the HeLa (
(b), 24hr (c), and 48hr (d) groups.

) and HeLaΔNQO2 (

) cell lines for the 18hr
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Supplementary Figure 3: Colony Formation Assay of HeLa Cells Treated with
Sunitinib.
HeLa (

) and HeLaΔNQO2 (

) cells were seeded at 300 cells per well in 6 well plates. a) Cells were

treated with varying concentrations of sunitinib or DMSO vehicle control with 3 wells per condition (n=3).
Treatments were conducted for 10 days, with media and drugs being replaced every 4 days. Cells were
fixed, stained with methylene blue and scanned. Images shown are representative of the replicates for each
treatment condition. b) Colonies were counted using Clono-Counter, data was plotted and analyzed in
Prism 8.4.2, statistical analysis performed was a two-way ANOVA with Tukey post-hoc test (* indicates Pvalue ≤ 0.05, ** indicates P-value ≤ 0.01, *** indicates P-value ≤ 0.001, **** indicates P-value ≤ 0.0001,
if comparison not displayed relationship is ns) (GraphPad Software Inc).
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Supplementary Figure 4: Colony Formation Assay of HCT116 Cells Treated with
Sunitinib and Chloroquine.
HCT116NQO2+ ( ), HCT1161ΔNQO2 (

), and HCT1162ΔNQO2 ( ) cells were seeded at 300 cells per well in

6 well plates. a) Cells were treated with varying concentrations of sunitinib or DMSO vehicle control and
either 0 µM or 2.5 µM chloroquine with 3 wells per condition (n=3). Treatments were conducted for 10
days, with media and drugs being replaced every 4 days. Cells were fixed, stained with methylene blue and
scanned. Images shown are representative of the replicates for each treatment condition. Colonies were
counted using Clono-Counter, data was plotted and analyzed in Prism 8.4.2 for (b) 0 µM and (c) 2.5 µM
chloroquine conditions respectively, statistical analysis performed was a two-way ANOVA with Tukey
post-hoc test (* indicates P-value ≤ 0.05, ** indicates P-value ≤ 0.01, *** indicates P-value ≤ 0.001, ****
indicates P-value ≤ 0.0001, if comparison not displayed relationship is ns) (GraphPad Software Inc).
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Supplementary Table 1: Proteins with Greater and Statistically Significant Average
LFQ Values in HCT116NQO2+ Relative to HCT116ΔNQO2 Cells.
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Supplementary Table 2: Proteins with Lower and Statistically Significant Average
LFQ Values in HCT116NQO2+ Relative to HCT116ΔNQO2 Cells.
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Supplementary Table 3: Targets of NQO2 Interacting Drugs and Determined
Structures of Drugs Bound to NQO2.
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Supplementary Table 4: Cellular Components with Significant Enrichment in
FunRich with Gene Names for Proteins with Significant Changes in Expression
from Mass Spectrometry Experiment as Input.
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Supplementary Table 5: Functional Enrichment Groupings for Proteins with
Higher Expression in HCT116NQO2+ Cells Using g:Profiler.
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Supplementary Table 6: Functional Enrichment Groupings for Proteins with
Decreased Expression in HCT116NQO2+ Cells Using g:Profiler.
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Supplementary Table 7: Functional Enrichment Groupings for Proteins with
Significant Changes in Expression Between HCT116NQO2+ Cells and NQO2
Knockout Cells Using g:Profiler.
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